| Excerpt | Reference |
|---|
| "Alzheimer's disease is an important problem of gerontology which manifested as serious loss of memory, especially of recent memory, decrease of brain weight." | ( Peng, JL; Wi, ZM, 1992) |
| "Alzheimer's disease is neuropathologically characterized by the occurrence of a minimum density of neurofibrillary tangles and neuritic plaques in the hippocampus and the association cortex of the brain." | ( Landsberg, JP; McDonald, B; Watt, F, 1992) |
| "Since Alzheimer's disease is exhibited by deterioration of the gray matter, the occurrence of elevated D-alanine levels in the gray matter of Alzheimer brains is a significant discovery and raises the question whether this enantiomer causes the degeneration of the gray matter proteins in Alzheimer's disease, or whether it is an effect of the disease." | ( Chavez, M; Cusano, G; D'Aniello, A; Fisher, GH; Petrucelli, L; Vetere, A, 1992) |
| "Alzheimer's disease is a degenerative disease characterized by the presence of numerous senile plaques and neurofibrillary tangles, primarily in the cortical areas of the brain." | ( Mera, SL, 1991) |
| "Alzheimer's disease is characterized by cerebral cortical atrophy, neuronal loss, neurofibrillary tangles, and neuritic plaques." | ( Volger, BW, 1991) |
| "Alzheimer's disease is a major public health problem, yet little is known about the potential oral consequences of the disease." | ( Baum, BJ; DeCarli, C; Friedland, RP; Ship, JA, 1990) |
| "Alzheimer's disease is characterized by progressive cognitive decline." | ( Hughes, JP; Larson, EB; Teri, L, 1990) |
| "Alzheimer's disease is a progressive deterioration of neuropsychological functioning." | ( Albert, SG; Caminal, ER; Grossberg, GT; Nakra, BR, 1989) |
| "Treatment of Alzheimer's disease is currently being investigated using intraventricular bethanechol." | ( Penn, RD, 1985) |
| "Alzheimer's Disease is associated with a defect in sympathetic nervous system function that is specifically linked to cognitive effort and appears early in the course of the disease." | ( Barnes, RF; Borson, S; Halter, JB; Raskind, MA; Veith, RC, 1989) |
| "Alzheimer's disease is associated with selective neuronal loss, the cause of which is undetermined." | ( Blass, JP; Finegan, JM; Sims, NR, 1987) |
| "Alzheimer's disease is a progressive neurodegenerative disease characterized by the development of large numbers of neurofibrillary tangles in certain neuronal populations." | ( Good, PF; Perl, DP, 1987) |
| "Alzheimer's disease is a slowly progressive disorder involving deterioration of both intellect and personality." | ( Cutler, NR; Narang, PK, 1986) |
| "Alzheimer's disease is a progressive neurodegenerative disease characterized neuropathologically by the development of large numbers of neurofibrillary tangles in certain neuronal populations of affected brains." | ( Pendlebury, WW; Perl, DP, 1986) |
| "The amyloid of Alzheimer's disease is similar in subunit size, composition but not sequence to the scrapie-associated fibril and its constituent polypeptides." | ( Beyreuther, K; Martins, RN; Masters, CL; Multhaup, G; Pottgiesser, J; Simms, G, 1985) |
| "Alzheimer's disease is a progressive degenerative brain disease of unknown etiology, characterized by the development of large numbers of neurofibrillary tangles and senile plaques in the brain." | ( Perl, DP, 1985) |
| "Alzheimer's disease is an insidious degenerative disease of the brain and is the leading cause of dementia in the U." | ( Conner, CS; Rathmann, KL, 1984) |
| "Alzheimer's disease is a common dementia of later life for which no effective treatments are yet available." | ( Shore, D; Wyatt, RJ, 1982) |
| "A central event in Alzheimer's disease is the conformational change from normally circulating soluble amyloid beta peptides (A beta) and tau proteins into amyloid fibrils, in the form of senile plaques and neurofibrillary tangles respectively." | ( Castano, EM; Frangione, B; Golabek, A; Kumar, RA; Prelli, F; Soto, C; Wisniewski, T, 1995) |
| "The risk of Alzheimer's disease is determined, in part, by inheritance of specific alleles of ApoE." | ( Goedert, M; Huang, DY; Roses, AD; Saunders, AM; Strittmatter, WJ; Weisgraber, KH, 1995) |
| "Late-onset Alzheimer's disease is linked to one isotype of apo E, apo E4." | ( Frangione, B; Golabek, AA; Kida, E; Wisniewski, KE; Wisniewski, T, 1995) |
| "Alzheimer's disease is characterized by cognitive and behavioral disturbances that are mediated in part by cholinergic brain deficits." | ( Antuono, PG, 1995) |
| "We hypothesize that Alzheimer's disease is caused by free radical damage to membranes of endocytic vesicles due to defective binding of iron and aluminium by Tf C2." | ( Carstens, ME; Potocnik, FC; Taljaard, JJ; van der Spuy, G; van der Walt, BJ; Van Rensburg, SJ, 1995) |
| "Alzheimer's disease is the most common cause of progressive intellectual failure." | ( Baron, P; Cassatella, MA; Ferrari, D; Meda, L; Otvos, L; Rossi, F; Szendrei, GI; Villalba, M, 1995) |
| "Alzheimer's disease is the most important cause of dementia, but its cause remains unknown." | ( Chun, MR; Mayeux, R, 1994) |
| "Alzheimer's disease is typified by the characteristic histopathological lesions of neurofibrillar plaques and tangles." | ( Avila, J; Bonay, P; Colaço, C; Ledesma, MD, 1994) |
| "Alzheimer's disease is associated with more pronounced noradrenergic and serotonergic denervation but, unlike normal aging, dopaminergic innervation of neostriatum is intact; although dopamine neurons are probably dysfunctional in this region." | ( DeKosky, ST; Palmer, AM, 1993) |
| "Alzheimer's disease is a progressive degenerative dementia characterized by the abundant presence of neurofibrillary tangles in neurons." | ( Cras, P; Martin, JJ; Mercken, M; Six, J; van de Voorde, A; Vandermeeren, M; Vanmechelen, E, 1993) |
| "Alzheimer's disease is characterized by changes in phospholipid metabolism leading to a perturbation in the levels of phosphomonoesters, including L-Phosphoserine (L-PS)." | ( Mason, RP; Pettegrew, JW; Trumbore, MW, 1996) |
| "Alzheimer's disease is characterized by the progressive accumulation of amyloid-beta protein (Abeta) in senile plaques and cerebral amyloid angiopathy." | ( Cleven, S; D'Urso, D; Frank, R; Ihl, R; Pavlakovic, G; Prikulis, I; Prior, R, 1996) |
| "Alzheimer's disease is characterized by progressive cerebral cholinergic neuronal degeneration." | ( del Rosario, R; Frey, KA; Gildersleeve, DL; Jung, YW; Kuhl, DE; Mulholland, GK; Raffel, DM; Sherman, PS; Van Dort, ME; Wieland, DM, 1996) |
| "Alzheimer's disease is a more common and malignant illness than was appreciated just 2 decades ago." | ( Keefover, RW, 1996) |
| "Alzheimer's disease is a progressive and incurable disease whose prevalence increases dramatically with age." | ( Feldman, H; Jefferies, WA; Kennard, ML; Yamada, T, 1996) |
| "Alzheimer's disease is characterized by the development of a degenerative condition in the elderly, associated with dementia." | ( Van Dyke, K, 1997) |
| "Alzheimer's disease is characterized by senile plaques composed of polymeric fibrils of beta amyloid (Abeta), a 39-42-amino acid peptide formed after proteolytic processing of the amyloid precursor protein (betaAPP)." | ( Bame, KJ; Danda, J; Hassall, A; Tumova, S, 1997) |
| "Alzheimer's disease is sporadic and has a late onset." | ( Hoyer, S, 1997) |
| "Alzheimer's disease is the most frequent cause of degenerative dementia." | ( Jacob, B; Lavenu, I; Lebert, F; Pasquier, F; Petit, H, 1997) |
| "Alzheimer's disease is the most common dementing illness affecting over 4 million Americans." | ( Henry, RG; Wekstein, DR, 1997) |
| "The prospect that Alzheimer's disease is caused by or related to estrogen deficiency, and treatable or even preventable by estrogen replacement therapy, is alluring." | ( Beckmann, CR, 1997) |
| "PS1 L250S familial Alzheimer's disease is an early onset form of Alzheimer's disease with clinical features similar to other reported familial Alzheimer's disease pedigrees, except that seizures were absent." | ( Collinge, J; Ellison, D; Fox, NC; Hardy, J; Harvey, RJ; Hutton, M; Roques, PK; Rossor, MN, 1998) |
| "Alzheimer's disease is characterized by the progressive deposition of two types of fibers in the affected brains, the amyloid fibers (consisting of the Abeta peptide, generating the amyloid plaques) and paired helical filaments (PHFs, made up of tau protein, forming the neurofibrillary tangles)." | ( Friedhoff, P; Mandelkow, E; Mandelkow, EM; Schneider, A, 1998) |
| "Alzheimer's disease is a devastating degenerative disorder of the central nervous system that results in gradual deterioration of cognitive function and severe alteration of personality." | ( Fisher, LJ; Gage, FH; Thal, LJ; Winkler, J, 1998) |
| "Alzheimer's disease is often unrecognized or misdiagnosed in its early stages." | ( Doraiswamy, PM; Pitchumoni, S; Steffens, DC; Tabrizi, S, 1998) |
| "Alzheimer's disease is characterized by degeneration of various structures in the brain, with development of amyloid plaques and neurofibrillary tangles." | ( Delagarza, VW, 1998) |
| "Alzheimer's disease is characterized by two types of fibrous aggregates in the affected brains, the amyloid fibers (consisting of the Abeta-peptide, generating the amyloid plaques), and paired helical filaments (PHFs; made up of tau protein, forming the neurofibrillary tangles)." | ( Davies, P; Friedhoff, P; Mandelkow, E; Mandelkow, EM; von Bergen, M, 1998) |
| "Because Alzheimer's disease is a heterogeneous disorder, the range of treatment responses likely will remain variable." | ( Larson, EB; Shadlen, MF, 1999) |
| "Alzheimer's disease is a common progressive neurodegenerative disease of unknown etiology." | ( Beckstrøm, H; Danbolt, NC; Dewar, D; Graham, DI; Haugeto, O; Julsrud, L; Lehre, KP; Storm-Mathisen, J, 1999) |
| "The dementia of Alzheimer's disease is caused by neuronal cell death." | ( Grammas, P; Moore, P; Weigel, PH, 1999) |
| "Alzheimer's disease is characterized by amyloid beta-peptide deposition, synapse loss, and neuronal death, which are correlated with cognitive impairments." | ( Begley, JG; Chan, S; Duan, W; Duff, K; Mattson, MP, 1999) |
| "Alzheimer's disease is suspected to be associated with oxidative stress, possibly due to the pro-oxidant properties of beta-amyloid present in the senile plaques." | ( Bondy, SC; Guo-Ross, SX; Yang, EY, 1999) |
| "Alzheimer's disease is associated with a loss in presynaptic cholinergic function." | ( Gemmell, HG; Murray, AD; Shanks, MF; Staff, RT; Venneri, A, 2000) |
| "Alzheimer's disease is associated with reductions in resting-state brain metabolism, as measured by PET, progressing with dementia severity." | ( Alexander, GE; Dani, A; Furey, ML; Guazzelli, M; Horwitz, B; Mentis, MJ; Pietrini, P; Rapoport, SI; Shapiro, MB, 2000) |
| "Alzheimer's disease is the most frequent neurodegenerative disorder in the aged population and is characterized by the deposition of the 40/42-residue amyloid beta protein (Abeta), a proteolytic fragment of the beta-amyloid precursor protein (APP)." | ( Smith, JD; Vincent, B, 2000) |
| "Alzheimer's disease is the most common cause of dementia in older people accounting for some 60% of cases with late-onset cognitive deterioration." | ( Birks, J; Flicker, L, 2000) |
| "Alzheimer's disease is the most common cause of dementia and is a primary degenerative disease of the brain of unknown cause." | ( Birks J, S; Melzer, D, 2000) |
| "Alzheimer's disease is characterized by the presence of insoluble, fibrous deposits composed principally of amyloid beta (Abeta) peptide." | ( Garzon-Rodriguez, W; Glabe, CG; Johnson, DA; Milton, S; Sepulveda-Becerra, M; Vega, A; Yatsimirsky, AK, 2000) |
| "The etiology of Alzheimer's disease is now known to be multifactorial." | ( De Villiers, JN; Kotze, MJ; Potocnik, FC; Taljaard, JJ; van Rensburg, SJ, 2000) |
| "Alzheimer's disease is characterised by the progressive deposition of the 4 kDa beta-amyloid peptide (A beta) in extracellular senile plaques in the brain." | ( Hooper, NM; Parkin, ET; Trew, AJ; Turner, AJ, 2000) |
| "Sporadic Alzheimer's disease is the most frequent form of dementia and appears to be associated with increasing age and certain genetic and environmental factors." | ( Adoue, D; Albarède, JL; Andrieu, S; Guyonnet, S; Nourhashémi, F; Ousset, PJ; Rolland, Y; Vellas, B, 2000) |
| "Alzheimer's disease is a chronic degenerative disorder of the central nervous system." | ( Bhattacharya, SK, 2000) |
| "Alzheimer's disease is the most common cause of dementia in older people." | ( Beppu, H; Birks, JS; Melzer, D, 2000) |
| "Alzheimer's disease is characterized by the deposits of the 4-kDa amyloid beta peptide (A beta)." | ( Eckman, C; Golde, T; Musunuru, U; Onstead, L; Pinnix, I; Sambamurti, K; Sridharan, A; Tun, H; Ziani-Cherif, C, 2001) |
| "Alzheimer's disease is one of the most challenging brain disorders and has profound medical and social consequences." | ( Delanty, N; Praticò, D, 2000) |
| "Alzheimer's disease is a rapidly worsening public health problem." | ( Bush, AI; Cuajungco, MP; Fagét, KY; Huang, X; Tanzi, RE, 2000) |
| "Neuron death in Alzheimer's disease is believed to be triggered by an increased production of amyloidogenic beta-amyloid peptides, involving both increased oxidative stress and activation of a conserved death program." | ( Bui, NT; Krohn, AJ; Lankiewicz, S; Luetjens, CM; Poppe, M; Prehn, JH, 2001) |
| "Alzheimer's disease is a debilitating neurodegenerative disorder that afflicts an increasing part of our ageing population." | ( Beffert, U; Herz, J, 2000) |
| "Alzheimer's disease is the most common cause of dementia and is characterised by an insidious onset and slow deterioration." | ( Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N, 2001) |
| "Alzheimer's disease is associated with a large cost burden, of which institutionalised care constitutes a major component." | ( Goa, KL; Lamb, HM, 2001) |
| "Alzheimer's disease is already an international problem of enormous significance, with an estimated 500,000 sufferers in the UK alone." | ( Wilkinson, D, 2001) |
| "Alzheimer's disease is correlated with the deposition of amyloid peptides in the brain of the patients." | ( Erdmann, VA; Fürste, JP; Lurz, R; Ylera, F, 2002) |
| "Alzheimer's disease is the most common neurodegenerative disorder in men and its incidence increases with the prolongation of life expectancy." | ( Dolezal, V; Kasparová, J, 2002) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of the beta-amyloid peptide and the hyperphosphorylation of the tau protein, among other features." | ( Alvarez, G; Avila, J; Bogónez, E; Díaz-Nido, J; Muñoz-Montaño, JR; Satrústegui, J, 2002) |
| "Alzheimer's disease is the major dementing disorder of the elderly that affects over 20 million peoples world-wide." | ( Brew, BJ; Guillemin, GJ, 2002) |
| "Alzheimer's disease is characterized by aggregates of tau protein." | ( Barghorn, S; Mandelkow, E, 2002) |
| "Alzheimer's disease is the most common cause of dementia, but Parkinson's disease also shows dementia in the later stages." | ( Mori, S, 2002) |
| "Alzheimer's disease is the most common cause of dementia in older people accounting for some 60% of cases with late-onset cognitive deterioration." | ( Birks, J; Flicker, L, 2003) |
| "Alzheimer's disease is associated with markedly impaired cerebral glucose metabolism as detected by reduced cortical desoxyglucose utilization, by altered activities of key glycolytic enzymes or by reduced densities of cortical glucose transporter subtypes." | ( Apelt, J; Bigl, M; Eschrich, K; Schliebs, R, 2003) |
| "1." | ( Brusco, LL; Caccuri, RL; Cardinali, DP; Castillo Thea, V; Cutrera, RA; Furio, AM; Pérez Lloret, S; Riccio, P, 2002) |
| "Alzheimer's disease is the most common cause of dementia associated with aging." | ( Martin, A, 2003) |
| "Alzheimer's disease is the main cause of dementia among the elderly." | ( Haroutunian, V; Laudon, H; Näslund, J; Religa, D; Styczynska, M; Winblad, B, 2003) |
| "Alzheimer's disease is defined in part by the intraneuronal accumulation of filaments comprised of the microtubule-associated protein tau." | ( Chirita, CN; Kuret, J; Necula, M, 2003) |
| "A hallmark of Alzheimer's disease is the deposition of plaques of amyloid beta peptide (Abeta) in the brain." | ( Kim, TW; Sun, Y; Tall, AR; Yao, J, 2003) |
| "Alzheimer's disease is associated with increased production and aggregation of amyloid-beta (Abeta) peptides." | ( Klein, PS; Lee, VM; Phiel, CJ; Wilson, CA, 2003) |
| "Alzheimer's disease is the commonest form of senile dementia, affecting almost 20 million people worldwide." | ( Estelrich, J; Gallardo, M; Sabaté, R, 2003) |
| "The pathogenesis of Alzheimer's disease is still unknown." | ( Gruys, E; Rofina, J; Schwippelova, Z; Skoumalova, A; Wilhelm, J, 2003) |
| "Alzheimer's disease is present in nearly half of individuals aged 85 years." | ( Butterfield, DA; Pocernich, CB, 2003) |
| "Alzheimer's disease is a triple proteinopathy with abnormalities of A-beta, tau, and alpha-synculein leading to a complex behavioral phenotype." | ( Cummings, JL, 2003) |
| "Alzheimer's disease is the most common cause of dementia in older people." | ( Birks, JS; Harvey, R, 2003) |
| "Alzheimer's disease is a biological process that involves the disruption of multiple neurochemical pathways." | ( Mintzer, JE, 2003) |
| "Alzheimer's disease is characterized by the development of senile plaques and neurofibrillary tangles, which are associated with neuronal destruction, particularly in cholinergic neurons." | ( DeLaGarza, VW, 2003) |
| "Alzheimer's disease is a progressive neurological condition that usually presents with short-term memory impairment, and then progresses to profound cognitive and physical disability." | ( Coll, PP; Fortinsky, RH; Kaplan, R; Song, C, 2003) |
| "The pathogenesis of Alzheimer's disease is strongly associated with the formation and deposition of beta-amyloid peptide (beta AP) in the brain." | ( Bobrowski, K; Hug, GL; Pogocki, D; Schöneich, C, 2003) |
| "Alzheimer's disease is often characterized by an increase in plasma cortisol without clinical evidence of hypercorticism." | ( Armanini, D; Basso, A; Fiore, C; Karbowiak, I; Mattarello, MJ; Milone, FF; Sartorato, P; Simoncini, M; Vecchio, F, 2003) |
| "Alzheimer's disease is defined in part by the intraneuronal accumulation of filaments comprised of the microtubule-associated protein tau." | ( Chirita, CN; Kuret, J, 2004) |
| "Alzheimer's disease is a neurodegenerative disorder characterised by the appearance of amyloid-beta (Abeta)-containing plaques and hyperphosphorylated tau-containing neurofibrillary tangles." | ( Milton, NG, 2004) |
| "Alzheimer's disease is characterized by the accumulation of amyloid-beta peptide, which is cleaved from the amyloid-beta precursor protein (APP)." | ( Bellingham, SA; Camakaris, J; La Fontaine, S; Lahiri, DK; Maloney, B; Multhaup, G, 2004) |
| "Late-onset sporadic Alzheimer's disease is a heterogeneous disorder." | ( Casserly, I; Topol, E, 2004) |
| "Alzheimer's disease is a progressive, neurodegenerative condition characterized by deficits in cognition, inability to perform activities of daily living, and alterations in behavior." | ( Dengiz, AN; Kershaw, P, 2004) |
| "Alzheimer's disease is characterized by amyloid peptide formation and deposition, neurofibrillary tangles, central cholinergic dysfunction, and dementia; however, the relationship between these parameters is not well understood." | ( Baumann, KH; Ebert, U; Erb, C; Hartmann, J; Klein, J; König, G; Popp, A, 2004) |
| "Alzheimer's disease is a neurodegenerative disorder associated with a decline in cognitive abilities." | ( Dani, JA; Zhang, L; Zhou, FM, 2004) |
| "Alzheimer's disease is a neurodegenerative disorder that affects the cholinergic, glutamatergic and monoaminergic systems in the neocortex and hippocampus." | ( Andin, J; Enz, A; Gentsch, C; Marcusson, J, 2005) |
| "Alzheimer's disease is a major illness of dementia characterized by the presence of amyloid plaques, neurofibrillary tangles, and extensive neuronal apoptosis." | ( Jana, A; Pahan, K, 2004) |
| "Alzheimer's disease is a neurodegenerative disorder associated with aging and cognitive decline." | ( Boyd-Kimball, D; Butterfield, DA; Mohmmad-Abdul, H; Sultana, R, 2004) |
| "Since Alzheimer's disease is associated with downregulation of the cholinergic system in the brain, its stimulation is expected to improve the patients' cognition, learning, and memory." | ( Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004) |
| "Alzheimer's disease is the fourth largest cause of death for people over 65 years of age." | ( Kaul, CL; Ramarao, P; Sonkusare, SK, 2005) |
| "Alzheimer's disease is pathologically characterized by neurofibrillary tangles and beta-amyloid plaques." | ( Geerts, H, 2005) |
| "Alzheimer's disease is characterized by brain deposition of toxic amyloid beta-peptide (Abeta), generated from the Abeta precursor protein (APP)." | ( Ge, YW; Lahiri, DK; Maloney, B, 2005) |
| "Alzheimer's disease is classified as a degenerative dementia while vascular dementia is known to be associated with atherothrombosis and classical vascular risk factors." | ( Gupta, A; Habubi, N; Majer, R; Morris, G; Pansari, K; Thomas, P; Watkins, A, 2005) |
| "Alzheimer's disease is characterized in part by the accumulation of full-length tau proteins into intracellular filamentous inclusions." | ( Chirita, CN; Congdon, EE; Kuret, J; Yin, H, 2005) |
| "Alzheimer's disease is characterized by both decreases in acetylcholinergic neurotransmission and increases in beta-amyloid accumulation." | ( Verhoeff, NP, 2005) |
| "Alzheimer's disease is common, incurable and disabling." | ( Geldmacher, DS, 2004) |
| "Alzheimer's disease is a progressive condition characterized by a loss of cognition, altered behavior, and a loss of functional ability, such as bathing, dressing, toileting, and organizing finances." | ( Borson, S; Kaufer, DI; Kershaw, P; Sadik, K, 2005) |
| "Alzheimer's disease is frequently associated with abnormalities in the hypothalamic pituitary adrenal axis." | ( Belanoff, J; DeBattista, C, 2005) |
| "The exact cause of Alzheimer's disease is still unknown; despite the dramatic progress in understanding." | ( Braun, HA; Narlawar, R; Schmidt, B, 2005) |
| "Alzheimer's disease is a chronic, progressive illness that requires long-term management." | ( Treinkman, A, 2005) |
| "Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families." | ( Desai, AK; Grossberg, GT, 2005) |
| "Alzheimer's disease is the most fatal neurodegenerative disorder wherein the process of amyloid-beta (Abeta) amyloidogenesis appears causative." | ( Adrian, M; Bohrmann, B; Döbeli, H; Lührs, T; Riek, R; Riek-Loher, D; Ritter, C; Schubert, D, 2005) |
| "Alzheimer's disease is associated with oxidative stress and changes in metal metabolism." | ( Hao, Q; Maret, W, 2005) |
| "Alzheimer dementia is a neurodegenerative disease characterised by loss of memory and other cognitive functions." | ( Landmark, K, 2006) |
| "One hallmark of Alzheimer's disease is the accumulation of amyloid beta-peptide, which invokes a cascade of oxidative damage to neurons that can eventually result in neuronal death." | ( Butterfield, DA; Calabrese, V; Coccia, R; De Marco, C; Joshi, G; Perluigi, M; Sultana, R, 2006) |
| "Alzheimer's disease is the most common cause of dementia in older people." | ( Birks, J; Harvey, RJ, 2006) |
| "Alzheimer's disease is characterized by the deposition of senile plaques that consist primarily of amyloid beta peptides." | ( Ackermann, BL; Blair, IA; Garner, C; Inoue, K; Oe, T, 2006) |
| "Alzheimer's disease is thought to be triggered by production of the amyloid beta (Abeta) peptide through proteolytic cleavage of the amyloid precursor protein (APP)." | ( Adams, JJ; Barnham, KJ; Cappai, R; Galatis, D; Kong, GK; Masters, CL; McKinstry, WJ; Parker, MW; Polekhina, G, 2005) |
| "Alzheimer's disease is a multifactorial, progressive, age-related neurodegenerative disease." | ( Anantharaman, M; Keller, JN; Kiningham, KK; Markesbery, WR; Murphy, MP; St Clair, DK; Tangpong, J, 2006) |
| "Alzheimer's disease is characterized by extracellular beta-amyloid plaques, intraneuronal Tau-inclusions and cell death of cholinergic neurons." | ( Humpel, C; Moser, KV; Stöckl, P, 2006) |
| "Alzheimer's disease is the most common form of dementia." | ( Cillier, AE; Ozturk, S, 2006) |
| "Alzheimer's disease is the most common cause of dementia." | ( Blennow, K; de Leon, MJ; Zetterberg, H, 2006) |
| "Alzheimer's disease is characterized by extracellular plaques of amyloid-beta peptide aggregates and intracellular neurofibrillary tangles composed of hyperphosphorylated tau leading to apoptotic cell death." | ( Marcilhac, A; Raynaud, F, 2006) |
| "Alzheimer's disease is the leading cause of dementia in the elderly, presenting itself clinically by progressive loss of memory and learning." | ( Bell, KF; Claudio Cuello, A, 2006) |
| "Alzheimer's disease is a progressive neurodegenerative disorder associated with aging and characterized by neurofibrillary tangles and amyloid plaques that deposit in the brain, triggering the neurodegenerative phenomena and leading to neuronal death." | ( Lu, KP; Pastorino, L, 2006) |
| "Alzheimer's disease is a progressive brain disorder which is neuropathologically characterized by an increased number of beta-amyloid plaques, tau pathology and synapse loss." | ( Humpel, C; Marksteiner, J; Pirchl, M, 2006) |
| "People with Alzheimer's disease are administered fewer analgesics and report less clinical pain than cognitively intact peers with similar painful diseases or injuries, prompting speculation about the likely impact of neurodegeneration on central pain processing." | ( Barber, JB; Cole, LJ; Duff, EP; Egan, GF; Farrell, MJ; Gibson, SJ, 2006) |
| "Alzheimer's disease is associated with abnormalities in the levels of some brain metabolites, including decreases in N-acetyl-aspartate (NAA) and increases in myo-inositol and choline levels." | ( Díaz, M; Fayed, N; Modrego, PJ; Pina, MA, 2006) |
| "Since Alzheimer's disease is known to be associated with down-regulation of the cholinergic and N-methyl-D-aspartate (NMDA) systems, most of these drugs inhibit acetylcholinesterase, potentiate the activity of nicotinic acetylcholine receptors (nAChRs), or modulate NMDA receptors." | ( Huang, J; Marszalec, W; Narahashi, T; Toth, PT; Yeh, JZ; Zhao, X, 2006) |
| "Alzheimer's disease is a fatal neurodegenerative disorder for which there are currently few treatments and no cure." | ( Patey, SJ, 2006) |
| "AD (Alzheimer's disease) is a neurodegenerative disorder characterized by self-assembly and amyloid formation of the 39-43 residue long Abeta (amyloid-beta)-peptide." | ( Lindhagen-Persson, M; Ohman, A; Olofsson, A; Sauer-Eriksson, AE, 2007) |
| "Alzheimer's disease is characterized by the presence of beta-amyloid fibril formation." | ( Adès, D; Garnier-Suillerot, A; Le Moyec, L; Migonney, V; Saengkhae, C; Salerno, M; Siove, A, 2007) |
| "Alzheimer's disease is an irreversible, progressive neurodegenerative disorder leading invariably to death, usually within 7-10 years after diagnosis and is the leading cause of dementia in the elderly." | ( Hu, Z; Huang, Z; Li, T; Zeng, L; Zhang, J, 2007) |
| "Alzheimer's disease is characterized by the presence of senile plaques in the brain, composed mainly of aggregated amyloid-beta peptide (Abeta), which plays a central role in the pathogenesis of Alzheimer's disease and is a potential target for therapeutic intervention." | ( Felszeghy, K; Horváth, J; Kasza, A; Kurunczi, A; Laroche, S; Párducz, A; Penke, B; Penke, Z; Sipos, E; Toldi, J, 2007) |
| "Alzheimer's disease is a debilitating neurodegenerative disorder associated with the abnormal self-assembly of amyloid-beta (Abeta) peptides into fibrillar species." | ( Griffin, MA; Shea, JE; Soto, P, 2007) |
| "Alzheimer's disease is characterized by severe neuronal disintegration supposed to be partly associated with amyloid pathology." | ( Alpár, A; Arendt, T; Gärtner, U; Seeger, G; Ueberham, U, 2007) |
| "Alzheimer's disease is a devastating neurological disorder." | ( Leonard, AS; McNamara, JO, 2007) |
| "Alzheimer's disease is an age-related neurodegenerative condition associated with cognitive decline." | ( Campbell, VA; Gowran, A, 2007) |
| "Alzheimer's disease is the fourth biggest killer in developed countries." | ( Barnham, KJ; Cappai, R; Crespi, GA; Kong, GK; McKinstry, WJ; Miles, LA; Morton, CJ; Ng, HL; Parker, MW, 2008) |
| "Alzheimer's disease is the most common form of dementia in industrialized countries." | ( Aguglia, E; Onor, ML; Trevisiol, M, 2007) |
| "Alzheimer's disease is the most common form of dementia in the elderly, and is characterised by extracellular amyloid plaques composed of the beta-amyloid peptide (A beta)." | ( Barnham, KJ; Hill, AF; Naylor, R, 2008) |
| "Alzheimer's disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of activities of daily living, and a variety of neuropsychiatric symptoms and behavioral disturbances." | ( Kumar, KP; Paramakrishnan, N; Samanta, MK; Santhi, K; Suresh, B; Wilson, B, 2008) |
| "Alzheimer's disease is the most common form of dementia in the elderly." | ( Hooijmans, CR; Kiliaan, AJ, 2008) |
| "Alzheimer's disease is characterized by the accumulation of neurotoxic amyloidogenic peptide Abeta, degeneration of the cholinergic innervation to the hippocampus (the septohippocampal pathway), and progressive impairment of cognitive function, particularly memory." | ( Coulson, EJ; Fox, B; Sotthibundhu, A; Sykes, AM; Thangnipon, W; Underwood, CK, 2008) |
| "Alzheimer's disease is the most common dementia and is pathologically characterized by deposition of amyloid-beta peptide (Abeta) into beta-amyloid plaques, neuronal injury and low-level, chronic activation of brain immunity." | ( Duman, RS; Flavell, RA; Laouar, Y; Mori, T; Pittenger, C; Szekely, CA; Tan, J; Town, T, 2008) |
| "Alzheimer's disease is defined pathologically by the presence of senile plaques, which consist primarily of extracellular aggregates of fibrillar Abeta peptide, and neurofibrillary tangles, which are abnormal, intracellular bundles of fibrillar tau protein." | ( Levine, H; Walker, LC, 2010) |
| "Alzheimer's disease is the most common form of dementia in the elderly, and it is characterized by elevated brain iron levels and accumulation of copper and zinc in cerebral beta-amyloid deposits (e." | ( Bush, AI; Tanzi, RE, 2008) |
| "Alzheimer's disease is the most common form of dementia in North America today." | ( Craig, LA; Hong, NS; Kopp, J; McDonald, RJ, 2008) |
| "Alzheimer's disease is characterized by the deposition of senile plaques and progressive dementia." | ( Bacskai, BJ; Goldman, ST; Hyman, BT; Kuchibhotla, KV; Lattarulo, CR; Wu, HY, 2008) |
| "Alzheimer's disease is a progressive neurodegenerative illness accounting for approximately 50% of all types of dementia in elderly people." | ( Devi, KP; Pandian, SK; Suganthy, N, 2009) |
| "Alzheimer's disease is characterized pathologically by the deposition of amyloid plaques." | ( Gupta, VB; Indi, SS; Rao, KS, 2009) |
| "Alzheimer's disease is currently thought to be a complex, multifactorial syndrome, unlikely to arise from a single causal factor; instead, a number of related biological alterations are thought to contribute to its pathogenesis." | ( Bolognesi, ML; Cavalli, A; Melchiorre, C, 2009) |
| "Alzheimer's disease is caused by Abeta accumulation in the brain cells combined with oxidative stress and inflammation." | ( Balasubramanian, K, 2006) |
| "Late-onset Alzheimer's disease is often connected with nutritional misbalance, such as enhanced cholesterol intake, deficiency in polyunsaturated fatty acids, or hypovitaminosis." | ( Endres, K; Fahrenholz, F; Hundt, J; Schneider, A; Tippmann, F, 2009) |
| "Alzheimer's disease is the most common neurodegenerative disease of the elderly and although some drugs may delay cognitive impairment, an effective treatment has not yet been found." | ( Bica, L; Cappai, R; Crouch, PJ; White, AR, 2009) |
| "Furthermore, Alzheimer's disease is also a major target for diagnosis by PET/SPECT imaging." | ( Ono, M, 2009) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by amyloid deposits and neurofibrillary tangles." | ( Belarbi, K; Blum, D; Buée, L; Burnouf, S; Caillierez, R; Demeyer, D; Grosjean, ME; Hamdane, M; Schindowski, K; Sergeant, N, 2009) |
| "Alzheimer's disease is the common cause of dementia in old people." | ( Lin, YS; Liu, MH; Sheu, SY; Sun, JS, 2009) |
| "Alzheimer's disease is characterized by neuropathological accumulations of amyloid beta(1-42) [A beta(1-42)], a cleavage product of the amyloid precursor protein (APP)." | ( Chauv, S; Hansen, LA; Masliah, E; Shaked, GM; Ubhi, K, 2009) |
| "Alzheimer's disease is an age-dependent neurodegenerative disorder that is characterized by a progressive decline in cognitive function." | ( Arita, K; Deguchi-Tawarada, M; Inoue, E; Katahira-Tayama, S; Matsui, C; Oda, Y; Sato, T; Takai, Y; Togawa, A; Yamauchi, E, 2009) |
| "Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques." | ( Dean, RA; Henley, DB; May, PC; Siemers, ER, 2009) |
| "The chemistry of Alzheimer's disease is largely centred on the amyloid beta-peptide, its formation, structure, and interactions with metals, membranes, proteins and other species." | ( Rauk, A, 2009) |
| "Alzheimer's disease is characterized by beta-amyloid plaques, tau pathology, cell death of cholinergic neurons, inflammatory processes and cerebrovascular damage." | ( Humpel, C; Pirchl, M, 2009) |
| "The hallmark of Alzheimer's disease is the pathological aggregation of tau proteins into paired helical filaments and neurofibrillary tangles." | ( Campos-Peña, V; Meraz-Rios, MA; Sánchez-Torres, C; Tapia-Ramírez, J, 2009) |
| "Alzheimer's disease is a chronic neurodegenerative disorder marked by a progressive loss of memory and cognitive function." | ( Gong, HL; Li, WP; Li, WZ; Wu, GC; Yao, YY; Yin, YY; Zhang, W, 2010) |
| "Alzheimer's disease is thought to be "common disease"." | ( Taniguchi, M; Urakami, K, 2009) |
| "Alzheimer's disease is nowadays the leading cause of dementia." | ( Ravasi, L; Semah, F, 2009) |
| "AD (Alzheimer's disease) is a neurodegenerative disease and the most common form of dementia." | ( Ariga, T; Yanagisawa, M; Yu, RK, 2010) |
| "Alzheimer's disease is a progressive, neurodegenerative disorder that is the leading cause of senile dementia, afflicting millions of individuals worldwide." | ( Bevan, DR; Lemkul, JA, 2010) |
| "Alzheimer's disease is a progressive neurodegenerative disease characterized by cognitive deficits." | ( Sugimoto, H, 2010) |
| "Alzheimer's disease is a chronic neurodegenerative disorder characterized by neuronal loss, cerebrovascular inflammation, and accumulation of senile plaques in the brain parenchyma and cerebral blood vessels." | ( Askarova, S; Lee, JC; Yang, X, 2010) |
| "Alzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available." | ( Boxer, AL; Kerchner, GA, 2010) |
| "Alzheimer's disease is a progressive, degenerative brain disease." | ( Bassil, N; Grossberg, GT; Thaipisuttikul, P, 2010) |
| "Alzheimer's disease is characterized by accumulation and deposition of Aβ peptides in the brain." | ( Callaghan, D; Huang, P; Juzwik, C; Shen, S; Xiong, H; Zhang, W, 2010) |
| "Alzheimer's disease is a neurodegenerative disorder." | ( Dogra, S; Kumar, A; Prakash, A, 2010) |
| "Alzheimer's disease is a complex genetic disease in the global prevalence of up to 15 million people." | ( Hou, Q; Li, J; Ma, J; Wang, C; Wang, W; Wang, Z; Xiao, Q, 2010) |
| "Alzheimer's disease is characterized by accumulation of amyloid deposits in brain, progressive cognitive deficits and reduced glucose utilization." | ( Ball, KK; Cruz, NF; Dienel, GA, 2010) |
| "Alzheimer's disease is a neurodegenerative disorder, characterized by progressive decline in memory and in social performance." | ( Adipepe, LF; Baloyannis, SJ; Costa, VG; Fotiou, DF; Manani, MG; Mavroudis, IA; Njau, SD; Psaroulis, D, 2010) |
| "Alzheimer's disease is a neurodegenerative pathology due to the presence of β-amyloid plaques at brain level and hippocampus level and associated with the loss of memory speech and learning." | ( Cataldi, A; Cerasa, LS; Di Stefano, A; Nasuti, C; Patruno, A; Pesce, M; Rapino, M; Sozio, P; Zara, S, 2011) |
| "Alzheimer's disease is hypothesized to be caused by an imbalance between β-amyloid (Aβ) production and clearance that leads to Aβ accumulation in the central nervous system (CNS)." | ( Bateman, RJ; Kasten, T; Mawuenyega, KG; Morris, JC; Munsell, L; Ovod, V; Sigurdson, W; Yarasheski, KE, 2010) |
| "Alzheimer's disease is a neurodegenerative disorder that is characterized by the accumulation of senile plaques containing amyloid β (Aβ) and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain." | ( Mohammadi, M; Yazdanparast, R, 2011) |
| "Alzheimer's disease is a progressive disorder with the moderate to severe stages generally characterized by significant cognitive, functional, and behavioral dysfunction." | ( Cummings, J; Sabbagh, M, 2011) |
| "Alzheimer's disease is neuropathologically characterized by amyloid β-protein (Aβ) deposition, resulting in neurotoxicity." | ( Shih, PH; Wu, CH; Yeh, CT; Yen, GC, 2011) |
| "Alzheimer's disease is one of the most devastating neurodegenerative disorders and is characterized by severe memory and cognitive decline." | ( Han, M; Liu, J; Liu, Y; Tan, Q; Wang, W; Wang, YY; Zhang, B; Zhang, JM; Zhang, XJ, 2011) |
| "A hallmark of Alzheimer's disease is production of amyloid β peptides resulting from aberrant cleavage of the amyloid precursor protein." | ( Flashner, E; Friedler, A; Raviv, U, 2011) |
| "Alzheimer's disease is a devastating disease whose recent increase in incidence rates has broad implications for rising health care costs." | ( Mascitelli, L; Seneff, S; Wainwright, G, 2011) |
| "Alzheimer's disease is a global, epidemic problem affecting mainly older adults with tremendous social and financial burdens." | ( , 2011) |
| "AD (Alzheimer's disease) is an age-associated neurodegenerative disorder where the accumulation of neurotoxic Aβ (amyloid β-peptide) in senile plaques is a typical feature." | ( Berrocal, M; Mata, AM; Sepúlveda, MR, 2011) |
| "Alzheimer's disease is characterized by β-amyloid accumulation in the central nervous system." | ( Abeti, R; Abramov, AY; Duchen, MR, 2011) |
| "Alzheimer's disease is a chronic neurodegenerative disorder resulting in part from the degeneration of cholinergic neurons in the brain." | ( Adam, DN; Greenspoon, J; Herrmann, N, 2011) |
| "Alzheimer's disease is a neurodegenerative disorder of the elderly and advancing age is the major risk factor for Alzheimer's disease development." | ( Begus-Nahrmann, Y; Biber, K; Heinrich, A; Hölter, SM; Langkopf, BH; Lie, DC; Liss, B; Rolyan, H; Rudolph, KL; Scheffold, A; Thal, DR; Vogt-Weisenhorn, DM; Wurst, W, 2011) |
| "Sporadic Alzheimer's disease is an age-related neurological and psychiatric disorder characterized by impaired energy metabolism." | ( Aggarwal, S; Bhateja, D; Dhull, DK; Dhull, RK; Jindal, A; Padi, SS, 2012) |
| "Alzheimer's disease is a progressive neurodegenerative disease that is biochemically characterized by the accumulation of amyloid beta (Aβ) peptides in the brain." | ( Borutaitė, V; Cižas, P; Jekabsonė, A; Morkūnienė, R, 2011) |
| "Alzheimer's disease is characterized by the accumulation of β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain." | ( Choe, YS; Lee, I; Lee, JH; Yang, J, 2011) |
| "Alzheimer's disease is the most devastating neurodegenerative disorder in the elderly, yet treatment options are severely limited." | ( Anekonda, TS; Quinn, JF, 2011) |
| "Alzheimer's disease is the most common form of neurodegenerative disorder and early detection is of great importance if new therapies are to be effectively administered." | ( Cooper, A; Foy, C; Lovestone, S; Murphy, D; Poppe, M; Simmons, A; Spenger, C; Wahlund, LO; Westman, E, 2011) |
| "Alzheimer's disease is characterized by the oligomerization and amyloid fibril formation of amyloid β-peptide (Aβ)." | ( Correia, I; Dorgeret, B; Khemtémourian, L; Lequin, O; Ongeri, S; Soulier, JL, 2011) |
| "Alzheimer's disease is associated with the abnormal self-assembly of the amyloid-β (Aβ) peptide into toxic β-rich aggregates." | ( Derreumaux, P; Li, H; Luo, Y; Wei, G, 2011) |
| "Alzheimer's disease is characterized by the deposition of aggregates of the β-amyloid peptide (Aβ) in the brain." | ( D'Errico, G; D'Ursi, AM; Grimaldi, M; Vitiello, G, 2012) |
| "Alzheimer's disease is a growing concern in the modern world." | ( Fukuda, T; Hasumura, T; Kumar, DS; Maekawa, T; Mathew, A; Morimoto, H; Nagaoka, Y; Venugopal, K; Yoshida, Y, 2012) |
| "Alzheimer's disease is commonly regarded as a loss of memory for past events." | ( Bussey, TJ; Cho, K; Heath, CJ; McTighe, SM; Romberg, C; Saksida, LM; Whitcomb, DJ, 2012) |
| "Alzheimer's disease is a major unmet medical need with pathology characterized by extracellular proteinaceous plaques comprised primarily of β-amyloid." | ( Ball, RG; Burke, JE; Chapnick, J; Close, J; Deshmukh, S; Diaz, D; Geng, X; Heidebrecht, R; Hendrix, J; Hughes, B; Jeliazkova-Mecheva, V; Kariv, I; Kattar, S; Kenefic, C; Kwei, G; Leach, JK; Li, C; Markarewicz, A; McNevin, MJ; Miller, T; Moses, P; Moxham, C; Moy, L; Munoz, B; Nikov, G; Savage, D; Shah, S; Shearman, M; Smotrov, N; Surdi, L; Tanga, F; Tempest, P; Xu, L; Yang, Z, 2012) |
| "Alzheimer's disease is a progressive neurodegenerative disorder mainly manifested by memory loss, personality changes, and cognitive dysfunction." | ( Hrubá, E; Korábecný, J; Kuca, K; Musílek, K; Nepovímová, E; Opletalová, V; Soukup, O; Spilovská, K; Zemek, F, 2012) |
| "Alzheimer's disease is characterized by the accumulation and deposition of Aβ peptides in human brains and Aβ induced free radical-mediated damage is one of the hypotheses." | ( Dai, J; Huang, P; Shen, S; Tian, X; Wang, J; Yang, L; Zhang, L, 2012) |
| "The aetiology of Alzheimer's disease is thought to include functional impairment of synapses and synapse loss as crucial pathological events leading to cognitive dysfunction and memory loss." | ( Andreyeva, A; Gottmann, K; Horstmann, K; Klapper, S; Korth, C; Müller-Schiffmann, A; Nieweg, K, 2012) |
| "Alzheimer's disease is the most common form of dementia leading to the irreversible loss of neurons, and Tau hyperphosphorylation has an important role in the pathology of Alzheimer's disease." | ( Chen, J; Chen, Y; Ding, J; Duan, P; Hu, M; Pan, J; Wang, C; Xu, C; Zhai, T, 2012) |
| "Alzheimer's disease is associated with a disruption of amyloid β (Aβ) homeostasis, resulting in the accumulation and subsequent deposition of Aβ peptides within the brain." | ( Karlo, JC; Landreth, GE; Mandrekar-Colucci, S, 2012) |
| "Central hallmark of Alzheimer's disease are senile plaques mainly composed of β-amyloid, which is a cleavage product of the amyloid precursor protein (APP)." | ( Egensperger, R; El Magraoui, F; Erdmann, R; Marcus, K; Meyer, HE; Müller, T; Pfeiffer, K; Platta, HW; Schrötter, A, 2012) |
| "Alzheimer's disease is a neurodegenerative disease characterized by the production of β-amyloid proteins and hyperphosphorylation of tau protein." | ( Li, L; Liu, J; Qin, K; Sun, D; Yan, X; Ye, R; Zhang, X; Zhao, G; Zhou, L; Zhu, Y, 2012) |
| "Alzheimer's disease is a complex age-dependent neurodegenerative disease where definitive diagnosis is only possible after autopsy and where there is a long prodromal or preclinical phase." | ( Bazenet, C; Lovestone, S, 2012) |
| "The etiology of Alzheimer's disease is thought to be linked to interactions between amyloid-β (Aβ) and neural cell membranes, causing membrane disruption and increased ion conductance." | ( Kukol, A; Poojari, C; Strodel, B, 2013) |
| "Alzheimer's disease is the leading cause of dementia in the elderly and is defined by two pathological hallmarks; the accumulation of aggregated amyloid beta and excessively phosphorylated Tau proteins." | ( Bush, AI; Camakaris, J; Greenough, MA, 2013) |
| "Alzheimer's disease is a devastating cureless neurodegenerative disorder affecting >35 million people worldwide." | ( Attar, A; Bitan, G; Frautschy, SA; Gale, GD; Grassi, C; Hayes, J; Jones, MR; Klärner, FG; Li Puma, DD; Lichti-Kaiser, K; Liu, T; Maiti, P; Riccardi, E; Ripoli, C; Schrader, T; Straudinger, JL; Tan, M; Tseng, CH; Xie, CW; Yang, F, 2012) |
| "A hallmark of Alzheimer's disease is the presence of senile plaques in human brain primarily containing the amyloid peptides Aβ42 and Aβ40." | ( Ahlijanian, M; Albayya, F; Blain, JF; Chesworth, R; Costa, D; De Strooper, B; Felsenstein, KM; Flood, D; Freeman, E; Havas, D; Hodgdon, H; Hopp, S; Hrdlicka, L; Hutter-Paier, B; Koenig, G; Lee, W; Leventhal, L; Miller, MJ; Nolan, S; Patzke, H; Portelius, E; Rogers, K; Scrocchi, L; Shapiro, G; Spaulding, D; Tu, Z; Vulsteke, V; Wen, M; Yang, Z; Zetterberg, H, 2012) |
| "Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis." | ( Matsuoka, N; Nagakura, A; Shitaka, Y; Yarimizu, J, 2013) |
| "The Alzheimer's disease is one of the most common neurodegenerative diseases that affect elderly population, due to the formation of β-amyloid protein aggregate and several symptoms, especially progressive cognitive decline." | ( Buarque, CD; Felcman, J; Ramos, JM; Silva, AM; Tenório, T, 2013) |
| "Alzheimer's disease is a worldwide metabolic disease and an economically costly disease to society, so more medicines need to be developed to treat this disease." | ( Fang, L; Jiang, H; Tao, Y; Yang, H; Yang, Y; Zhang, H; Zhou, H, 2013) |
| "Alzheimer's disease is a progressive neurodegenerative disorder affecting millions of people." | ( De Caluwé, J; Dupont, G, 2013) |
| "Alzheimer's disease is characterized by progressive cognitive disturbances and neurotransmitter dysfunction." | ( Bond, RA; Eriksen, JL; Forkuo, GS; Vollert, C, 2013) |
| "Alzheimer's disease is the most common form of dementia." | ( Eskici, G; Gur, M, 2013) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by accumulation of Aβ peptide aggregates in the brain." | ( Abrahams, JP; Gräslund, A; Luo, J; Wärmländer, SK, 2013) |
| "Alzheimer's disease is a neurodegenerative disease that is associated with the abnormal accumulation of amyloid-β." | ( Becker, A; Johnson, KA; Sabuncu, MR; Sepulcre, J; Sperling, R, 2013) |
| "Alzheimer's disease is a progressive neurodegenerative disease that entails impairments of memory, thinking and behavior and culminates into brain atrophy." | ( Akopian, G; Brinton, RD; Cadenas, E; Sancheti, H; Walsh, JP; Yin, F, 2013) |
| "Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein." | ( Aisen, PS; Doody, RS; Farlow, M; He, F; Iwatsubo, T; Joffe, S; Kieburtz, K; Mohs, R; Raman, R; Sethuraman, G; Siemers, E; Sun, X; Thomas, RG; Vellas, B, 2013) |
| "Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language." | ( Farlow, M; Ferris, SH, 2013) |
| "Alzheimer's disease is associated with accumulation of extracellular beta amyloid peptide 42 (Aβ42) which may induce DNA damage and reduce cellular regenerative potential." | ( Fenech, M; Lee, SL; Thomas, P, 2014) |
| "Alzheimer's disease is a progressive degenerative disease of the brain marked by gradual and irreversible declines in cognitive functions." | ( Ahmad, K; Baig, MH; Boukli, F; Ghalem, S; Kamal, MA; Merad, M; Soufi, W, 2014) |
| "Alzheimer's disease is characterized by two notorious protein aggregates in the brain: extracellular senile plaques mainly consisting of amyloid-β peptides and tau-protein-derived intracellular paired helical filaments." | ( Boländer, A; Czech, C; Goetschy, V; Heyny-von Haußen, R; Kieser, D; Mall, G; Schmidt, B; Scholz, C, 2014) |
| "Alzheimer's disease is the commonest cause of dementia in the elderly, but its pathological determinants are still debated." | ( Andrade-Moraes, CH; Carvalho, LR; Castro-Fonseca, E; da Silva, CG; Ferretti-Rebustini, RE; Gomes, BV; Grinberg, LT; Guimarães, DM; Jacob-Filho, W; Leite, RE; Lent, R; Oliveira, LM; Oliveira-Pinto, AV; Parente-Bruno, DR; Pasqualucci, CA; Polichiso, L; Rodriguez, RD; Szczupak, D, 2013) |
| "Alzheimer's disease is an age-related neurodegenerative disease characterized by deterioration of cognition and loss of memory." | ( Cadenas, E; Díaz Brinton, R; Kanamori, K; Patil, I; Ross, BD; Sancheti, H, 2014) |
| "Although Alzheimer's disease is a brain disorder, a number of peripheral alterations have been found in these patients; however, little is known about how the key genes involved in the pathophysiology express in peripheral cells such as lymphocytes during normal compared to neuropathological ageing." | ( Aranda-Abreu, GE; Hernández, ME; Herrera-Rivero, M; Soto-Cid, A, 2013) |
| "Alzheimer's disease is an advanced dementia." | ( Gharaei, H; Shadlou, H, 2014) |
| "Alzheimer's disease is the most common cause of the declarative memory disorder: 30-40% cases of dementia among all of age groups, and 50-60% among the people older 65 years." | ( Mukhin, VN, 2013) |
| "The prevalence of Alzheimer's disease is increasing rapidly in the absence of truly effective therapies." | ( Talbot, K, 2014) |
| "AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population." | ( Batalha, VL; Blum, D; Boison, D; Buée, L; Burnouf, S; Coelho, JE; Flaten, V; Hamdane, M; Humez, S; Laurent, C; Lopes, LV; Sandau, U, 2014) |
| "Alzheimer's disease is the most common form of age-related neurodegenerative dementia." | ( Donnelly, PS; Hayne, DJ; Lim, S, 2014) |
| "Alzheimer's disease is an age-related neurodegenerative disease and a synaptic function defect disease, the clinical symptoms are mainly progressive cognitive impairment, affecting patient's social function." | ( Cheng, XL; Li, MK, 2014) |
| "Alzheimer's disease is a progressive neurodegenerative disorder." | ( Fukumoto, K; Horiuchi, H; Jin, S; Kawanokuchi, J; Mizoguchi, H; Mizuno, T; Suzumura, A; Takeuchi, H, 2014) |
| "Alzheimer's disease is the most common and lethal neurodegenerative disorder." | ( Angeloni, C; Hrelia, S; Zambonin, L, 2014) |
| "Alzheimer's disease is the most common form of dementia in the elderly." | ( Mattace-Raso, F, 2014) |
| "Alzheimer's disease is an irreversible neurodegenerative disorder that is characterized by the abnormal aggregation of amyloid-β into neurotoxic oligomers and plaques." | ( Ahn, YG; Kim, DJ; Kim, HY; Kim, MS; Kim, Y; Kim, YH; Kong, JY; Lee, MH; Lee, SH, 2014) |
| "Alzheimer's disease is a neurodegenerative disorder clinically characterized by cognitive dysfunction and by deposition of amyloid plaques, neurofibrillary tangles in the brain." | ( Attia, M; El Din, MA; Kassem, LA; Khairallah, MI; Yassin, NA; Zekri, M, 2014) |
| "Risk of developing Alzheimer's disease is increased by older age, genetic factors, and several medical risk factors." | ( Barnard, ND; Bush, AI; Ceccarelli, A; Cooper, J; de Jager, CA; Erickson, KI; Fraser, G; Kesler, S; Levin, SM; Lucey, B; Morris, MC; Squitti, R, 2014) |
| "Alzheimer's disease is a slowly progressing disorder, in which pathophysiological abnormalities, detectable in vivo by PET biomarkers, precede clinical symptoms by many years to decades." | ( Perani, D, 2014) |
| "Alzheimer's disease is a consequence of an imbalance between the generation and clearance of amyloid-beta peptide in the brain." | ( Di, W; Fang, Y; Lin, J; Qi, W; Shi, X; Xiao, Z; Zhang, A; Zheng, Z; Zhou, G; Zhu, Y, 2014) |
| "Alzheimer's disease is associated with the accumulation of Aβ (amyloid β)-peptides in the brain." | ( Canobbio, I; Guidetti, GF; Manganaro, D; Oliviero, B; Pula, G; Torti, M; Vara, D, 2014) |
| "Alzheimer's disease is a complex disease characterized by overlapping phenotypes with different neurodegenerative disorders." | ( Ahmad, Y; Castillo-Carranza, DL; Guerrero-Muñoz, MJ; Jackson, GR; Kayed, R; Krishnamurthy, S; Lasagna-Reeves, CA; Paulucci-Holthauzen, AA; Sengupta, U, 2014) |
| "Alzheimer's disease is an age-dependent progressive neurodegenerative disorder that results in impairments of memory and cognitive function." | ( Cho, EJ; Choi, YY; Fujii, H; Kim, HY; Maeda, T; Shibamoto, T; Yokozawa, T, 2014) |
| "Alzheimer's disease is a neurodegenerative disorder that is the most common cause of dementia in the elderly today." | ( Fitzgerald, S; Lauer, SL; Levy, E; Lopez-Guzman, M; Nixon, RA; Schoen, C; Wilson, DA; Xu, W, 2014) |
| "Alzheimer's disease is a chronic neurodegenerative disorder characterized by progressive dementia and deterioration of cognitive function." | ( Kim, MH; Kim, SH; Yang, WM, 2014) |
| "Alzheimer's disease is the most common neurodegenerative disorder in the world." | ( Fonar, G; Samson, AO, 2014) |
| "Alzheimer's disease is a neurodegenerative disorder associated with the deposition of the peptide amyloid-beta (Aβ) in senile plaques and cerebral vasculature." | ( Liu, F; Tian, W; Wei, T; Xie, G, 2015) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by a loss of memory and spatial orientation." | ( Baldauf, K; Reymann, KG; Schneider, F; Wetzel, W, 2015) |
| "Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by extensive deposition of fibrillar amyloid-β (Aβ) in the brain." | ( Davis, J; Liao, MC; Ou-Yang, MH; Robinson, JK; Van Nostrand, WE; Xu, F, 2015) |
| "Alzheimer's disease is a neurodegenerative disorder which is the most common cause of dementia." | ( Mukhin, VN, 2013) |
| "Alzheimer's disease is a neurodegenerative pathology with unmet clinical needs." | ( Brea, JM; Carotti, A; Castro, M; Catto, M; Domínguez, JL; Fernández-Nieto, F; Paleo, MR; Porto, S; Sardina, FJ; Sussman, F; Villaverde, MC, 2015) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by deposition of β-amyloid (Aβ) fibrils accompanied with progressive neurite loss." | ( Chang, PT; Chen, CS; Chen, GS; Chern, JW; Chern, TR; Deore, RR; Huang, CW; Kung, FL; Lai, SY; Lin, JH; Talekar, RS; Yang, MY; Ye, QQ; Yu, CW, 2015) |
| "A major feature of Alzheimer's disease is the accumulation of β-amyloid (Aβ) peptide in the brain." | ( Aguayo, LG; Espinoza, MP; Gallegos, S; Opazo, C; Peters, C, 2015) |
| "Alzheimer's disease is one of the devastating illnesses mankind is facing in the 21st century." | ( Govindaraju, T; Manjithaya, R; Rajasekhar, K; Suresh, SN, 2015) |
| "Alzheimer's disease is the most common cause of dementia in the elderly." | ( Argüelles, S; de Pablos, RM; Delgado-Cortés, MJ; Espinosa-Oliva, AM; Herrera, AJ; Machado, A; Mauriño, R; Sarmiento, M; Venero, JL; Villarán, RF, 2015) |
| "Alzheimer's disease is associated with metabolic deficits and reduced mitochondrial function, with the latter due to the effects of oligomeric amyloid beta peptide (AβO) on the respiratory chain." | ( Arce, PM; Coleman, PD; Hecht, SM; Khdour, OM; Mastroeni, D, 2015) |
| "Alzheimer's disease is a fatal neurodegenerative disorder with a complex etiology." | ( Bajda, M; Brus, B; Gobec, S; Guzior, N; Malawska, B; Rakoczy, J, 2015) |
| "Alzheimer's disease is a rising threat for modern societies as more and more people reach old age." | ( Fu, Y; Link, P; Wetterauer, B; Wink, M, 2015) |
| "Patients with Alzheimer's disease are at increased risk for unprovoked seizures and epilepsy compared with age-matched controls." | ( Hiltunen, M; Pitkänen, A; Tanila, H; Viswanathan, J; Ziyatdinova, S, 2015) |
| "Alzheimer's disease is the commonest cause of dementia affecting older people." | ( Birks, JS; Grimley Evans, J, 2015) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by extracellular amyloid plaque deposits, mainly composed of amyloid-beta peptide and intracellular neurofibrillary tangles consisting of aggregated hyperphosphorylated tau protein." | ( Binder, S; De Souza Silva, MA; Dere, D; Dere, E; Huston, JP; Zlomuzica, A, 2016) |
| "Alzheimer's disease is the most common cause of dementia." | ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| "Alzheimer's disease is a grave social problem in an aging population." | ( Coelho, H; Fernandes, A; Iranzo, O; Maycock, CD; Rocha, J; Simplício, AL; Ventura, MR; Vila-Real, H, 2015) |
| "Alzheimer's disease is an irreversible, progressive neurodegenerative disorder." | ( Barage, SH; Sonawane, KD, 2015) |
| "Alzheimer's disease is characterized by neuronal loss and cerebral accumulation of amyloid-β protein (Aβ) and lowering the generation of Aβ is a pivotal approach in the strategy of Alzheimer's disease treatment." | ( Kami, A; Komano, H; Liu, J; Liu, S; Maeda, T; Matsumoto, Y; Michikawa, M; Murakami, S; Sugakawa, Y; Tanabe, C; Zou, K, 2015) |
| "Alzheimer's disease is the common cause of dementia characterized by the accumulation of amyloid-β produced by breakage of amyloid-β precursor protein (APP)." | ( Li, J; Zhang, FF, 2015) |
| "Alzheimer's disease is a devastating and invariably fatal neurodegenerative brain disorder with no cure." | ( Du, X; Liu, Q; Wang, C, 2016) |
| "Alzheimer's disease is the most common cause of dementia and occurs commonly in patients 65 and older." | ( Aronson, MD; Daneschvar, HL; Smetana, GW, 2015) |
| "The cause of Alzheimer's disease is incompletely defined, and no truly effective therapy exists." | ( Bredesen, DE, 2015) |
| "Alzheimer's disease is accompanied by attention deficits that exacerbate its other cognitive symptoms." | ( Fraser, P; Lambe, EK; McLaurin, J; Proulx, É, 2015) |
| "Alzheimer's disease is a disease that is resulted from increased plasma osmolality both the excessive consumption of animal-based proteins and reduction of sodium intake, that resulted to increase plasma osmolality." | ( Hahr, JY, 2015) |
| "Alzheimer's disease is a devastative neurodegenerative disorder." | ( Dowlathabad, MR; Magisetty, O; Mannar, SN; Raichurkar, KP, 2016) |
| "Alzheimer's disease is associated with the accumulation within the brain of amyloid-β (Aβ) peptides that damage synapses and affect memory acquisition." | ( Bate, C; McHale-Owen, H; Nolan, W; Osborne, C; West, E; Williams, A, 2016) |
| "Alzheimer's disease is a progressive neurodegenerative disease characterized by loss of hippocampal neurons leading to memory deficits and cognitive decline." | ( Ellis, DZ; Krishnamoorthy, RR; Krishnamoorthy, VR; Stankowska, DL, 2017) |
| "Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation." | ( Agbaba, D; Benchekroun, M; Brindisi, M; Brogi, S; Butini, S; Campiani, G; Esteban, G; Filipic, S; Gemma, S; Ismaili, L; Marco-Contelles, J; Nikolic, K; Refouvelet, B; Unzeta, M, 2017) |
| "Alzheimer's disease is the most frequent age-related dementia, and is currently without treatment." | ( Elkahloun, AG; Hafko, R; Saavedra, JM, 2016) |
| "Alzheimer's disease is characterized by deposition of the amyloid β-peptide (Aβ) in brain tissue of affected individuals." | ( Althoff-Ospelt, G; Barucker, C; Hossain, S; Lopez del Amo, JM; Multhaup, G; Prade, E; Reif, B; Sarkar, R; Zhong, Y, 2016) |
| "Preclinical Alzheimer's disease is defined as biomarker evidence of Alzheimer's pathological changes in cognitively healthy individuals." | ( Blennow, K; Breteler, MM; de Strooper, B; Frisoni, GB; Salloway, S; Scheltens, P; Van der Flier, WM, 2016) |
| "Alzheimer's disease is associated with the formation of plaques in the brain primarily comprised of aggregates of a 42 amino acid protein called amyloid-β." | ( Donnelly, PS; Hayne, DJ; Lange, JL; McLean, CA; Roselt, P; White, JM, 2016) |
| "Alzheimer's Disease is the leading neurodegenerative cause of dementia." | ( Ergun, MA; Guntekin, S; Karaman, Y; Panpalli Ates, M, 2016) |
| "Alzheimer's disease is characterized by redistribution of the tau protein pool from soluble to aggregated states." | ( Harrington, CR; Lai, RY; Wischik, CM, 2016) |
| "Alzheimer's disease is a multifactorial syndrome, for which effective cures are urgently needed." | ( Caporaso, R; Minarini, A; Rosini, M; Simoni, E, 2016) |
| "Alzheimer's disease is a multifactorial disease that is characterized mainly by Amyloid-β (A-β) deposits, cholinergic deficit and extensive metal (copper, iron)-induced oxidative stress." | ( Bednarikova, Z; Brezova, V; Drostinova, L; Gazova, Z; Hamulakova, S; Hrabinova, M; Jomova, K; Jun, D; Kristian, P; Kuca, K; Lauro, P; Poprac, P; Sepsova, V; Soukup, O; Valko, M, 2016) |
| "Alzheimer's disease is a multifaceted disease." | ( Matheou, CJ; Viles, JH; Younan, ND, 2016) |
| "As Alzheimer's disease is characterized by multiple pathological changes, a biomarker panel reflecting co-occurring pathology will likely be most useful for early detection." | ( Asthana, S; Bendlin, BB; Berman, SE; Blennow, K; Carlsson, CM; Clark, LR; Gleason, CE; Johnson, SC; Koscik, RL; Nicholas, CR; Okonkwo, OC; Racine, AM; Rowley, HA; Zetterberg, H, 2016) |
| "Alzheimer's disease is characterized by the presence of amyloid plaques in the brain." | ( Barnham, KJ; Donnelly, PS; Hayne, DJ; McLean, CA; Villemagne, VL; White, JM, 2016) |
| "Alzheimer's disease is a complex multifactorial disorder, therefore therapy should likely address not only the cholinergic system but also additional neurotransmitters." | ( Galimberti, D; Scarpini, E, 2016) |
| "Our hypothesis -- Alzheimer's disease is brain wound healing gone awry at least in some cases -- could be tested by measuring progression with biomarkers for the four stages of wound healing in humans or appropriate animal models." | ( Lehrer, S; Rheinstein, PH, 2016) |
| "Persons with Alzheimer's disease are at an increased risk of pneumonia, but the comparative risks during specific antidementia treatments are not known." | ( Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2017) |
| "Alzheimer's disease is the most frequent cause of dementia in older patients." | ( Depypere, H; Sieben, A; Vierin, A; Weyers, S, 2016) |
| "Alzheimer's disease is the most common neurodegenerative disorder." | ( Eleutherio, EC; França, MB; Lima, KC, 2017) |
| "Alzheimer's disease is characterized in part by the intracellular misfolding and aggregation of tau protein." | ( Hinckley, SH; Kuret, J; Lin, L; Nanavaty, N, 2017) |
| "Alzheimer's disease is a neurodegenerative disorder with insidious onset and slow progression." | ( Høgh, P, 2017) |
| "Alzheimer's disease is an age-related neurodegenerative disorder characterized by a progressive decline in cognitive function due to the extracellular accumulation and deposition of beta-amyloid peptide (Aβ)." | ( Asl, SS; Komaki, A; Sarihi, A; Shahidi, S; Zargooshnia, S, 2017) |
| "Alzheimer's disease is a still untreatable multifaceted pathology, and drugs able to stop or reverse its progression are urgently needed." | ( Bartolini, M; Belluti, F; Bisi, A; Cavalli, A; Falchi, F; Feoli, A; Gobbi, S; Montanari, S; Pruccoli, L; Rampa, A; Tarozzi, A, 2017) |
| "Alzheimer's disease is associated with the aggregation of amyloid-β (Aβ) peptides into oligomers and fibrils." | ( Björkeroth, J; Esbjörner, EK; Lindberg, DJ; Rocha, S; Wesén, E, 2017) |
| "Alzheimer's disease is characterized by intracerebral deposition of β-amyloid (Aβ)." | ( Bruestle, O; Fraering, PC; Gerber, H; Koch, P; Rajendran, L; Siegel, G, 2017) |
| "Alzheimer's disease is a progressive neurodegenerative disease." | ( Bin, L; Feng, Q; Liu, Z; Peng, W; Xu, M; Zhou, J, 2017) |
| "Alzheimer's disease is the most common form of dementia accounting for 50-60% of all dementia cases." | ( Halliday, GM; Kumfor, F; Piguet, O, 2017) |
| "Alzheimer's disease is a common tauopathy where fibril formation and aggregates are the hallmark of the disease." | ( Aguilar Sandoval, F; Ardiles, A; Areche, C; Caballero, J; Caballero, L; Cornejo, A; Machuca, L; Melo, F; Muñoz, P; Perry, G, 2017) |
| "Alzheimer's disease is still incurable and neurodegenerative, and there is a lack of detection methods with high sensitivity and specificity." | ( Du, T; Han, S; Jiang, H; Jiang, X; Lai, L; Li, X; Liu, X; Rehman, FU; Wang, X; Zhao, C; Zheng, Y, 2017) |
| "Alzheimer's disease is a challenge of the utmost importance for contemporary society." | ( Contreras-García, J; Guallar, V; Pantaleone, S; Peccati, F; Riffet, V; Sodupe, M; Solans-Monfort, X, 2017) |
| "Alzheimer's disease is a common age associated neurodegenerative disorder associated with an elevated risk of seizures that may be fundamentally connected to cognitive dysfunction." | ( Nuñez, A; Reyes-Marin, KE, 2017) |
| "Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys cognitive skills and the ability to perform the simplest tasks." | ( Badgaiyan, RD; Baron, D; Blum, K; Dunston, GM; Gold, MS; Gondré-Lewis, MC; McLaughlin, T; Modestino, EJ; Steinberg, B, 2018) |
| "Late onset Alzheimer's disease is the most common form of dementia and at present its aetiology is largely undetermined." | ( Grabowski, P; Rehman, I; Robinson, N, 2018) |
| "Alzheimer's disease is the most common major neurocognitive disorder with substantial social and economic impacts." | ( Gold, J; Grossberg, GT; Hinds, S; Khoury, R; Patel, K, 2017) |
| "Alzheimer's disease is a neurodegenerative disorder with Amyloid-β plaques onset, synaptic damage, and cognitive decline." | ( Ding, H; Elgehama, A; Gao, J; Geng, J; Guo, W; Jiang, C; Li, X; Liu, W; Sun, Y; Xiong, Y; Xu, Q; Yang, X, 2018) |
| "Alzheimer's disease is the most common form of dementia and is considered to be caused by the conformational change of Aβ monomers, from their native monomeric states, to form Aβ oligomers/aggregates in the brain." | ( Agrawal, N; Skelton, AA, 2018) |
| "Alzheimer's disease is a devastating neurodegenerative disease eventually leading to dementia." | ( Agbemenyah, HY; Arce, FT; Benito, E; Benz, R; Camilleri, A; Caruana, M; Eichele, G; Fischer, A; Fuhrmann, M; Giese, A; Gillman, AL; Griesinger, C; Grigorian, G; Jain, G; Kaurani, L; Korte, M; Lal, R; Lee, J; Leonov, A; Martinez Hernandez, A; Rezaei-Ghaleh, N; Ryazanov, S; Schneider, A; Urbanke, H; Vassallo, N; Wagner, J; Wilken, P; Zweckstetter, M, 2018) |
| "Alzheimer's disease is a common and devastating disease characterized by aggregation of the amyloid-β peptide." | ( Auwerx, J; Beck, JS; Counts, SE; D'Amico, D; Mouchiroud, L; Moullan, N; Potenza, F; Rietsch, S; Romani, M; Schmid, AW; Sorrentino, V; Zhang, H, 2017) |
| "Alzheimer's disease is a progressive neurodegenerative disease characterized by the accumulation of amyloid-β (Aβ) in the brain." | ( Bate, C; Williams, A, 2018) |
| "Alzheimer's disease is a neurodegenerative disorder that affects the central nervous system." | ( Bunner, W; Do, K; Huang, H; Laing, BT; Landry, T; Li, P; Lu, Q; Matsubara, T; Mersaud, N; Yuan, Y, 2018) |
| "Alzheimer's disease is increasingly considered a large-scale network disconnection syndrome, associated with progressive aggregation of pathological proteins, cortical atrophy, and functional disconnections between brain regions." | ( Brodtmann, A; Connelly, A; Dhollander, T; Mito, R; Raffelt, D; Rowe, CC; Salvado, O; Tournier, JD; Vaughan, DN; Villemagne, VL, 2018) |
| "Alzheimer's disease is debilitating neurodegenerative disorder in the elderly." | ( Dolezal, R; Gorecki, L; Janockova, J; Jun, D; Korabecny, J; Kuca, K; Malinak, D; Mezeiova, E; Nepovimova, E; Soukup, O; Spilovska, K, 2018) |
| "Alzheimer's disease is one of the most common age‑associated diseases that frequently leads to memory disorders, cognitive decline and dementia." | ( Chen, L; Fang, L; Wang, C; Zang, G, 2018) |
| "Alzheimer's disease is a severe brain illness that causes vast numbers of nerve cells in the brain to die, driven by the production and deposition of amyloid beta (Aβ) peptides." | ( Grover, A; Kumari, A; Rajput, R; Shrivastava, N; Somvanshi, P, 2018) |
| "Alzheimer's disease is a neurodegenerative brain disease resulting from the deterioration of neuronal cells and vascular dementia, the latter of which results from cerebrovascular disorders." | ( Ha, MS; Ha, SM; Jung, YS; Kim, DY; Kim, JH; Kim, JW, 2018) |
| "Alzheimer's disease is the most common form of dementia affecting a large proportion of aged people." | ( Casamenti, F; Lapucci, A; Nardiello, P; Pantano, D; Stefani, M, 2018) |
| "Alzheimer's disease is a multifactorial disorder for which there is no disease-modifying treatment yet." | ( Alquézar, C; Bartolomé, F; Campillo, NE; Carro, E; Del Cerro, P; González-Naranjo, P; Martín-Requero, Á; Páez, JA; Pérez, C, 2018) |
| "Alzheimer's disease is the most common form of dementia." | ( Cardona-Gómez, GP; Sabogal-Guáqueta, AM; Vargas-Restrepo, F, 2018) |
| "Alzheimer's disease is the most common cause of dementia in older people." | ( Birks, JS; Harvey, RJ, 2018) |
| "Alzheimer's disease is characterized by accumulation of amyloid plaques and tau aggregates in several cortical brain regions." | ( Attems, J; Daum, G; Flunkert, S; Hoeller, C; Hutter-Paier, B; Kerschbaumer, B; Loeffler, T; Neddens, J; Niederkofler, V; Temmel, M, 2018) |
| "The exact cause of Alzheimer's disease is not fully explored, although a number of risk factors have been recognized, including high plasma concentration of homocysteine (Hcy)." | ( Adamkov, M; Kalenska, D; Kovalska, L; Kovalska, M; Lehotsky, J; Tatarkova, Z; Tomascova, A; Tothova, B, 2018) |
| "Alzheimer's disease is characterized by aggregated β-amyloid and tau proteins, but the clinical presentations and patterns of brain atrophy vary substantially." | ( Hansson, O; Jögi, J; Mattsson, N; Ohlsson, T; Ossenkoppele, R; Palmqvist, S; Smith, R; Stomrud, E; Strandberg, O, 2018) |
| "Alzheimer's disease is a leading cause of morbidity and mortality with no cure and only limited treatment available." | ( Allan, K; Campbell, FM; Grant, C; Horgan, GW; Langston, RF; McLean, FH; Morris, AC; Polanski, AJ; Williams, LM, 2018) |
| "Alzheimer's disease is a neurodegenerative disorder mainly characterized by β-amyloid deposit and tau hyperphosphorylation with no curative treatments." | ( Chen, X; Fan, S; Fang, W; Guo, R; Jing, X; Lei, M; Liao, W; Liu, J; Liu, X; Ma, Q; Tao, E; Zhang, X; Zheng, Y, 2018) |
| "Alzheimer's disease is a tauopathy characterized by pathological fibrillization of tau protein to form the paired helical filaments (PHFs), which constitute neurofibrillary tangles." | ( Al-Hilaly, YK; Baddeley, T; Harrington, CR; Pollack, SJ; Raulin, AC; Rickard, JE; Schellenberger, P; Serpell, LC; Simpson, M; Storey, JMD; Wischik, CM, 2018) |
| "Alzheimer's disease is the most common form of dementia and is a major contributor to morbidity and mortality in older Australians." | ( Bell, JS; Garcia-Ptacek, S; Hilmer, SN; Tan, EC, 2018) |
| "Alzheimer's disease is the most common neurodegenerative disease, and many patients also present with vascular dysfunction." | ( Borghgraef, P; Dresselaers, T; Govaerts, K; Himmelreich, U; Kremer, A; Lechat, B; Struys, T; Van Leuven, F, 2019) |
| "Alzheimer's disease is characterized by the formation of plaques, composed primarily of the amyloid-β 1-42 (Aβ) peptide in the brain, resulting in neurodegeneration." | ( Caldwell, GA; Caldwell, KA; Griffin, EF; Yan, X, 2018) |
| "Alzheimer's disease is characterized by progressive disruption of cholinergic neurotransmission and impaired cognitive functions." | ( Al-Amin, MM; Ashikur Rahman, M; Mahmud, W; Pervin, MS; Ridwanul Islam, SM; Zinchenko, A, 2019) |
| "Alzheimer's disease is a progressive neurodegenerative disorder causing common health problem with increasing age." | ( Aykac, A; Ertaş, B; Kılınc, O; Orun, O; Ozbeyli, D; Şen, A; Sener, G; Uncu, M, 2019) |
| "Alzheimer's disease is likely to be caused by copathogenic factors including aggregation of Aβ peptides into oligomers and fibrils, neuroinflammation, and oxidative stress." | ( Belluti, F; Bisceglia, F; Catanzaro, M; De Lorenzi, E; Gervasoni, S; Lanni, C; Seghetti, F; Serra, M; Verga, L; Vistoli, G; Zusso, M, 2019) |
| "The burden of Alzheimer's disease is becoming increasingly unsustainable, and given the last decade of clinical trial failures, a renewed understanding of the disease mechanism is called for, and trialling of new therapeutic approaches to slow disease progression is warranted." | ( Ayton, S; Bush, AI; Nikseresht, S, 2019) |
| "Alzheimer's disease is characterized by the aggregation of Amyloid-β (Aβ) peptide into oligomers, fibrils and plaques." | ( Horn, AHC; Huraskin, D, 2019) |
| "Alzheimer's disease is one of severe neurological diseases for which no effective treatment is currently available." | ( Gaffke, L; Majkutewicz, I; Mantej, J; Myślińska, D; Osiadły, M; Pierzynowska, K; Podlacha, M; Węgrzyn, A; Węgrzyn, G, 2019) |
| "Alzheimer's disease is a leading cause of morbidity worldwide." | ( Archer, H; Ballard, C; Bannister, C; Brooks, DJ; Busza, G; Coulthard, E; Donaldson, A; Edison, P; Femminella, GD; Frangou, E; Harrison, J; Holmes, C; Hölscher, C; Junaid, K; Karim, S; Knight, L; Koranteng, P; Kshemendran, S; Lawrence, R; Love, SB; Macharouthu, A; Malik, N; Mate, V; McFarlane, B; McGuinness, B; Nilforooshan, R; Passmore, AP; Prasanna, A; Ridha, BH; Ritchie, C; Russell, G; Tadros, G; Thacker, S; Underwood, BR; Walker, Z, 2019) |
| "Alzheimer's disease is a widespread type of neurodegenerative dementia that mainly affects the elderly." | ( Camargo, AJ; Camargo, LTFM; Ribeiro, L; Rodrigues, ACC; Vieira, I, 2019) |
| "Alzheimer's disease is a neurodegenerative disorder characterized by a progressive decline of cognitive abilities as well as bone loss." | ( Abo El-Ella, DM; Ali, AA; El-Emam, SZ; El-Sayed, RM; Shahat, AS, 2019) |
| "Alzheimer's disease is a devastating neurodegenerative disease that requires pharmacological intervention." | ( Chen, X; Yu, L; Yu, Z, 2019) |
| "Late onset Alzheimer's disease is the most common form of dementia for which about 30 susceptibility loci have been reported." | ( Allen, ND; Amouyel, P; Baker, E; Bossù, P; Brayne, C; Cruchaga, C; Dichgans, M; Escott-Price, V; Frizzati, A; FröLich, L; Gill, M; Goate, AM; Grozeva, D; Hardy, J; Harwood, JC; Heun, R; Hill, M; Holmans, P; Holmes, C; Ivanov, D; Jessen, F; Jones, L; Leonenko, G; Maier, W; Mead, S; Morgan, BP; Morgan, K; Passmore, P; Peters, O; Powell, J; Ramirez, A; Schellenberg, GD; Seshadri, S; Sims, R; Spalletta, G; Williams, J, 2019) |
| "Alzheimer's disease is the most common form of dementia, that affects millions of people worldwide." | ( Agrawal, N; Skelton, AA, 2019) |
| "Alzheimer's disease is a common cause of dementia, and is usually treated with medications that elevate acetylcholine levels." | ( Duran-Lengua, M; Machado-Alba, JE; Valladales-Restrepo, LF, 2019) |
| "Alzheimer's disease is associated with the production of Cu rich aβ fibrils." | ( Creech, J; Dallas, J; Le Borgne, M; Moynier, F, 2019) |
| "Alzheimer's disease) is switched with an object that differs in some way (e." | ( Birk, RH; Fletcher, JR, 2019) |
| "Alzheimer's disease is a chronic progressive neurodegenerative disorder associated with depletion of acetylcholine." | ( Farswan, M; Madaan, T; Razdan, BK; Setya, S; Talegaonkar, S, 2019) |
| "Alzheimer's disease is a devastating condition characterized by a progressive and slow brain decay in elders." | ( Brazaca, LC; Martín, A; Moreto, JR; Tehrani, F; Wang, J; Zucolotto, V, 2019) |
| "Alzheimer's disease is one of the most common causes of dementia nowadays, and its prevalence increases over time." | ( Amor-Gutiérrez, O; Arce-Varas, N; Costa-García, A; Costa-Rama, E; Fernández-Sánchez, MT; Martínez-Rodríguez, C; Novelli, A, 2020) |
| "Alzheimer's disease is the leading cause of dementia, effecting majority of aged people worldwide." | ( Balaraman, E; Chinnathambi, S; Das, R; Gorantla, NV, 2020) |
| "Alzheimer's disease is a serious neurologic disorder that cannot be cured completely." | ( Akiba, M; Kino, Y; Kinoshita, K; Koyama, K; Sato, JI, 2020) |
| "Alzheimer's disease is characterized by amyloid β aggregation and cholinergic neurodegeneration." | ( Abdelfatah, S; Bouajila, J; Dhouafli, Z; Efferth, T; Hayouni, EA; Khelifi, I; Ksouri, R; Tourrette, A, 2020) |
| "Alzheimer's disease is considered to be associated with the dyshomeostasis of metal ions such as aluminum, zinc, copper, and ferric ions." | ( Kumari, A; Panda, D; Rane, JS, 2020) |
| "Alzheimer's disease is the most common form of progressive neurodegenerative dementia of the aged brain." | ( Ahmed, KA; Attia, HN, 2020) |
| "Alzheimer's disease is a neurodegenerative disorder, and most common form of dementia afflicting over 35 million people worldwide." | ( Banerjee, A; Lipp, L; Sharma, D; Singh, J, 2020) |
| "Alzheimer's disease is a devastating neurodegenerative disorder." | ( Adams, CD, 2020) |
| "Alzheimer's disease is a progressive condition that damages the brain over time." | ( Gruber, J; Kaur, P; Kibat, C; Lam, VYM; Lim, CH; Mathuru, AS; Teo, E; Tolwinski, NS; Zhu, F, 2020) |
| "Alzheimer's disease is a progressive neurodegenerative disorder and patients suffer from memory loss, a decline in language skill and impairment in other cognitive functions." | ( Dastan, D; Ebadi, A; Olyaie, SS, 2021) |
| "Alzheimer's disease is type of dementia in which cognitive functions get declined." | ( Awasthi, A; Corrie, L; Gulati, M; Kumar Singh, S; Vishwas, S, 2020) |
| "Alzheimer's disease is a neurodegenerative disorder for which there is a continuous search of drugs able to reduce or stop the cognitive decline." | ( Luca, A; Paduraru, L; Stanciu, GD; Stefanescu, R; Tamba, BI, 2020) |
| "Alzheimer's disease is a neuropathological disease with symptoms such as language problems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, behavioral changes, and memory loss." | ( Bülbül, EÖ; Karantas, ID; Mutlu, G; Okur, ME; Okur, NÜ; Siafaka, PI, 2020) |
| "Alzheimer's disease is characterized by the aggregation of amyloid-beta (Aβ) peptide into plaques and neurofibrillary tangles." | ( Dai, L; Fu, CX; Xu, YJ; Yuan, XY, 2021) |
| "The prevalence of Alzheimer's Disease is rising, in part due to increase in the medium age of residents in developed countries." | ( Komorowska, J; Szukiewicz, D; Wątroba, M, 2020) |
| "Alzheimer's disease is an irreversible, progressive brain disorder manifested with symptoms like loss of memory (known as dementia), personality changes, loss of cognition, impaired movement, confusion, deteriorated planning and thought process." | ( Fayaz, F; Khan, FA; Kumar, B; Mishra, J; Pandey, M; Pottoo, FH; Sahoo, PK, 2021) |
| "Alzheimer's disease is the most common neurodegenerative disorder." | ( Ahmed, IMM; Bellia, F; Greco, V; La Mendola, D; Messina, L; Naletova, I; Rizzarelli, E; Satriano, C; Sciuto, S; Vaccaro, S, 2020) |
| "Alzheimer's disease is an age related progressive neurodegenerative disorder characterized by decline in cognitive functions, such as memory loss and behavioural abnormalities." | ( Dixit, MP; Kotagale, NR; Rahmatkar, SN; Raut, P; Taksande, BG; Umekar, MJ, 2021) |
| "Alzheimer's disease is one of the leading health problems characterized by the accumulation of Aβ and hyperphosphorylated tau that account for the senile plaque formations causing extensive cognitive decline." | ( Basar, MK; Baykal, AT; Coskun, J; Gurel, B; Kiris, I; Mroczek, T; Sahin, B, 2021) |
| "Furthermore, Alzheimer's disease is associated with hyperphosphorylated tau which self-assembles into neurofibrillary tangles from excessive amounts of phosphate in the brain and central nervous system." | ( Brown, RB, 2020) |
| "Alzheimer's disease is now a most prevalent neurodegenerative disease of central nervous system leading to dementia in elderly population." | ( Akkinepally, R; Garige, AK; Garlapati, A; Kulkarni, R; Macha, B; Palabindala, R, 2022) |
| "Alzheimer's disease is majorly associated with intracellular accumulation of Tau into paired helical filaments and tangles." | ( Chidambaram, H; Chinnathambi, S, 2022) |
| "Alzheimer's disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks." | ( Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M, 2021) |
| "Alzheimer's disease is the predominant source of dementia." | ( Abdel-Daim, MM; Alghamdi, HA; Alghamdi, WM; Alkahtane, AA; Alkahtani, S; Almutairi, B; Hasnain, MS; Khan, MM, 2021) |
| "Alzheimer's disease is a neurodegenerative disorder affecting predominantly the memory of the affected individual." | ( Abdelnaser, A; Azar, J; El-Fawal, HAN; Yousef, MH, 2021) |
| "Alzheimer's disease is a multifactorial disorder characterized by extracellular accumulation of amyloid-β (Aβ) and intracellular accumulations of neurofibrillary tangles." | ( Deshmukh, R; Kumari, S, 2021) |
| "Alzheimer's disease is a neurodegenerative disorder that results in progressive and irreversible central nervous system impairment, which has become one of the severe issues recently." | ( Mah, SH; Vanessa, VV, 2021) |
| "Alzheimer's disease is a destructive nervous system disease which causes structural, biochemical and electrical abnormalities inside the human brain and results due to genetic and various environmental factors." | ( Alghamdi, HA; Alhamdi, HW; Alshammari, FA; Attique, SA; Nawaz, MZ; Yan, W, 2022) |
| "Alzheimer's disease is a devastating neurodegenerative disease with a dramatically increasing prevalence and no disease-modifying treatment." | ( Beattie, JH; Bradley, A; Brough, D; Cook, J; Daniels, MJD; Drinkall, S; Gordon, MJ; Green, JP; Hoyle, C; Kennedy, PT; Lawrence, CB; Mather, AE; Peters, R; Rivers-Auty, J; Spence, HG; Tapia, VS; Tzeng, TC; White, CS; Yu, S, 2021) |
| "Alzheimer's disease is a neurodegenerative disease which severely impacts the health of the elderly." | ( Chen, J; Eliezer, D; Lu, Y; Tan, Q; Wu, C; Wu, Q; Xiao, S; Yang, J; Zhong, S, 2021) |
| "Alzheimer's disease is one of the neurodegenerative disorders caused by neuronal degeneration and apoptosis in brain." | ( Bai, QK; Zhao, ZG, 2022) |
| "A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide." | ( Andersen, SW; Apostolova, LG; Ardayfio, PA; Brys, M; Duggan Evans, C; Lo, AC; Mintun, MA; Salloway, SP; Shcherbinin, S; Sims, JR; Skovronsky, DM; Sparks, J; Wessels, AM, 2021) |
| "Alzheimer's disease is a chronic and progressive neurodegenerative disorder, which is the most common cause of dementia worldwide." | ( Akarlar, BA; Arioz, BI; Bagriyanik, HA; Durur, DY; Genc, S; Keskinoglu, P; Olcum, M; Ozlu, N; Tufekci, KU; Yener, G, 2021) |
| "Alzheimer's disease is a progressive neurodegenerative disorder with cognitive and memory impairment." | ( Akula, A; Bitra, VR; Rapaka, D; Ummidi, R, 2021) |
| "Alzheimer's disease is a progressive neurodegenerative disease, and its incidence is expected to increase as the global population ages." | ( Huang, W; Huang, Y; Ma, L; Wang, R; Yang, G, 2021) |
| "Alzheimer's disease is a common neurodegenerative disease in the elderly population and a leading cause of dementia." | ( Ahmad, MK; Garg, RK; Mahdi, AA; Srivastava, S; Verma, AK; Yadav, J, 2021) |
| "Alzheimer's disease is a growing general health concern with huge implications for individuals and society." | ( Alizadeh, L; Naghdi, N; Ramezani, S; Riazi, GH; Shasaltaneh, MD, 2022) |
| "Alzheimer's disease is the most common age-related neurodegenerative disorder." | ( Celardo, I; Fedele, G; Loh, SHY; Martins, LM; Yu, Y, 2021) |
| "Alzheimer's disease is a neurodegenerative disorder associated with age, and is characterized by pathological markers such as amyloid-beta plaques and neurofibrillary tangles." | ( Fung, ML; Lim, LW; Ng, J; Roy, J; Tsui, KC, 2021) |
| "Alzheimer's disease is the most significant type of neurodegenerative disorder plaguing societies globally." | ( Azzam, G; Leow, BG; Najimudin, N; Tan, FHP; Ting, ACJ; Watanabe, N, 2021) |
| "Alzheimer's disease is a progressive, age-related, and neurodegenerative disease characterized by mental decline." | ( Khodaei, F; Khoshnoud, MJ; Mojarad, M; Rashedinia, M; Sahragard, A; Zarshenas, MM, 2021) |
| "Diabetes and Alzheimer's disease are common chronic illnesses in the United States and lack clearly demonstrated therapeutics." | ( Aldhowayan, H; Babu, JR; Ding, XW; Geetha, T; Li, R; Robinson, M, 2021) |
| "The mechanism of Alzheimer's disease is closely associated with the aggregation of amyloid-β protein and causes neurotoxicity and extracellular accumulation in the brain and to intracellular neurofibrillary tangles caused by tau protein hyperphosphorylation in the brain tissue." | ( Chuang, Y; Van, I; Xu, Y; Zhao, Y, 2021) |
| "Alzheimer's disease is a neurodegenerative disease caused by the deposition and accumulation of amyloid-β (Aβ) peptides in the brain neurons." | ( Abolmaali, SS; Dahri, M; Maleki, R; Miri Jahromi, A; Mohammadgholian, M; Nikzad, A; Rahmanian, M, 2022) |
| "Alzheimer's disease is a chronic neurodegenerative disorder driven by uncontrolled extracellular deposition of β-amyloid (Aβ) in the amyloid plaques and intracellular accumulation of hyperphosphorylated tau protein." | ( Koushki, K; Majeed, M; Sahebkar, A; Sathyapalan, T; Shahbaz, SK, 2022) |
| "Alzheimer's disease is characterized by the accumulation of amyloid beta (Aβ) and Tau aggregates in the brain, which induces various pathological events resulting in neurodegeneration." | ( Acharya, A; Govindaraju, T; Ila, H; Murugan, NA; Ramesh, M, 2021) |
| "Alzheimer's disease is increasingly being recognized as an immune-mediated disease of brain." | ( Gupta, M; Weaver, DF, 2022) |
| "Alzheimer's disease is associated with multiple risk factors and is the most common type of dementia." | ( Buawangpong, N; Chattipakorn, N; Chattipakorn, SC; Pinyopornpanish, K; Siri-Angkul, N, 2022) |
| "Alzheimer's disease is often associated with circadian rhythm disorders, chronic insomnia, and sleep apnea-hypopnea syndrome." | ( Carrier, J; Dang-Vu, TT; Moderie, C, 2022) |
| "Alzheimer's disease is a multifaceted, highly genetically heterogeneous neurodegenerative disease." | ( Fu, K; He, X; Liu, W; Xu, J; Xu, P; Zhang, Z, 2022) |
| "Alzheimer's disease is characterized by the presence of extraneuronal amyloid plaques composed of amyloid-beta (Aβ) fibrillar aggregates in the brains of patients." | ( Becker, S; Giller, K; Griesinger, C; Karami, L; Moosavi-Movahedi, AA; Nedaei, H; Rezaei-Ghaleh, N; Saboury, AA, 2022) |
| "Alzheimer's disease is the most common type of neurodegenerative disease that causes dementia and has become a global health problem that seriously impacts human health today." | ( Huang, Y; Ji, X; Li, S; Wu, J; Yu, L, 2023) |
| "Alzheimer's disease is the most common neurodegenerative disease and currently poses a significant socioeconomic problem." | ( Panayides, JL; Riley, DL; Stander, A; van der Westhuizen, CJ, 2022) |
| "Alzheimer's disease is histopathologically well defined by the presence of amyloid deposits and tau-related neurofibrillary tangles in crucial regions of the brain." | ( Cebolla, AM; Cheron, G; Marquez-Ruiz, J; Ris, L; Ristori, D, 2022) |
| "Alzheimer's disease is a chronic disease, and the long-term treatment of chronic diseases has always been a concern." | ( Gong, J; Kuang, W; Lin, X; Liu, J; Wang, J; Wu, S; Yin, Q, 2022) |
| "Alzheimer's disease is a progressive and irreversible neurodegenerative disease that accounts for 70-80% of dementia in the elderly." | ( Nadh, AG; Nair, AS; Revikumar, A; Sudhakaran, PR, 2022) |
| "Alzheimer's disease is a multifactorial disease that exhibits cognitive deficits, neuronal loss, amyloid plaques, neurofibrillary tangles and neuroinflammation in the brain." | ( Chaudry, O; Figueiredo-Pereira, ME; Liu, Q; Oliveros, G; Qiu, Y; Rockwell, P; Serrano, PA; Wallace, CH; Xie, L, 2023) |
| "Alzheimer's disease is the most prevalent cause of dementia in the elderly." | ( Calfío, C; Churruca, M; González, A; Maccioni, RB, 2022) |
| "Alzheimer's disease is understood to be caused by amyloid fibrils and oligomers formed by aggregated amyloid-β (Aβ) peptides." | ( Itoh, SG; Okumura, H, 2022) |
| "Alzheimer's disease is a chronic and progressive brain neurodegenerative disease affecting over 30 million people globally." | ( Dong, J; Sang, Z; Tang, L; Wang, K, 2022) |
| "Alzheimer's disease is a progressive neurodegenerative disease and is one of the leading causes of dementia worldwide." | ( Banerjee, R; Rajesh Kannan, R; Saleem, S, 2022) |
| "Alzheimer's disease is the most common cause of dementia in the elderly population." | ( Ali, RH; Ali, SK, 2022) |
| "Alzheimer's disease is a chronic neurodegenerative ailment and the most familiar type of dementia in the older population with no effective cure to date." | ( Ahmad, SS; Almalki, AS; Khalid, M; Khan, H, 2022) |
| "Alzheimer's disease is characterized by the accumulation of extracellular amyloid beta (Aβ) and abnormally hyperphosphorylated intracellular tau filaments in neurons." | ( Alcolea, D; Blanco-Vaca, F; Borràs, C; Escolà-Gil, JC; Mercer, A; Sirisi, S; Tondo, M, 2022) |
| "Alzheimer's disease is the most common form of dementia, and the prodromal phases of Alzheimer's disease can last for decades." | ( Christoffersen, M; Frikke-Schmidt, R; Nordestgaard, LT, 2022) |
| "Alzheimer's disease is well characterized as a general cause of dementia, which includes issues with memory, language, problem-solving, and other cognitive behaviours, such as disabled perception as well as trouble talking due to degeneration of neurons." | ( Chawla, PA; Kumar, A; Kumar, D; Nehra, B; Singh, D, 2023) |
| "Alzheimer's disease is caused by extracellular amyloid fibrils containing the peptide Amyloid beta (Aβ) accumulating in the brain." | ( Bhattacharya, S, 2023) |
| "Alzheimer's disease is becoming a common disorder of the elderly population due to shrinkage of the brain size with age and many other neurological complications." | ( Dang, S; Kaur, A; Nigam, K; Tyagi, A, 2022) |
| "Alzheimer's disease is becoming a common disorder of the elderly population due to shrinkage of the brain size with age and many other neurological complications." | ( Dang, S; Kaur, A; Nigam, K; Tyagi, A, 2022) |
| "Alzheimer's disease is becoming a common disorder of the elderly population due to shrinkage of the brain size with age and many other neurological complications." | ( Dang, S; Kaur, A; Nigam, K; Tyagi, A, 2022) |
| "Alzheimer's disease is one of the most common neurodegenerative diseases worldwide and carries a huge social burden." | ( Levin, OS; Vasenina, EE; Veryugina, NI, 2022) |
| "Alzheimer's disease is one of the most common neurodegenerative diseases worldwide and carries a huge social burden." | ( Levin, OS; Vasenina, EE; Veryugina, NI, 2022) |
| "Alzheimer's disease is one of the most common neurodegenerative diseases worldwide and carries a huge social burden." | ( Levin, OS; Vasenina, EE; Veryugina, NI, 2022) |
| "Alzheimer's disease is imposing a growing social and economic burden worldwide, and effective therapies are urgently required." | ( Adamson, JSP; Ball, SR; Jiang, X; Kassiou, M; Knowles, TPJ; Kwan, AH; Lo, V; McKenzie, ADJ; Meisl, G; Rutledge, PJ; Sanz-Hernandez, M; Sullivan, MA; Sunde, M; Todd, MH; Werry, EL; Zimmermann, MR, 2023) |
| "Alzheimer's disease is characterized by the presence in the brain of amyloid plaques formed by the aberrant deposition of the amyloid-β peptide (Aβ)." | ( Chia, S; Gabriel, JM; Gilmer, M; Habchi, J; Joshi, P; Limbocker, R; Perni, M; Vendruscolo, M; Yang, X, 2023) |
| "Tau spreading in Alzheimer's disease is mediated by cell surface heparan sulfate (HS)." | ( Jin, W; Linhardt, RJ; Lu, C; Wang, C; Wang, L; Zhang, F; Zhang, W; Zhao, J; Zhu, Y, 2023) |
| "Alzheimer's disease is a prevalent form of dementia, particularly among the elderly population." | ( Aleti, S; Asharaf, S; Gadam, S; Makhanasa, D; Prajjwal, P; Tariq, H; Vora, N; Yamparala, A, 2023) |
| "Alzheimer's disease is regarded as a common neurodegenerative disease that may lead to dementia and the loss of memory." | ( Abu Hajleh, MN; Al-Dmour, RH; Al-Dujaili, EAS; Al-Saraireh, YM; Al-Tawarah, NM; Alqaraleh, M; Jaradat, AQ; Khleifat, KM, 2023) |
| "The incidences of Alzheimer's disease are increasing nowadays, and constant efforts are being made to develop a medicinal agent for this disease." | ( Bhardwaj, M; Grover, P; Malhotra, A; Mehta, L; Rohilla, S, 2023) |
| "Progression of Alzheimer's disease is accompanied by the appearance of extracellular deposits in the brain tissues of patients with characteristic supramolecular morphology (amyloid plaques) the main components of which are β-amyloid isoforms (Aβ) and biometal ions (zinc, copper, iron)." | ( Kozin, SA, 2023) |
| "Alzheimer's disease is a progressive neurological disorder characterized by the intracellular accumulation of Tau protein aggregates." | ( Chandrashekar, M; Chinnathambi, S; Dubey, T, 2023) |
| "Alzheimer's disease is a neurologic disorder characterized by the accumulation of extracellular deposits of amyloid-β (Aβ) fibrils in the brain of patients." | ( Bellier, JP; Hayashi, D; Ishibe, T; Matsui, A; Mera, Y; Nakamura, Y; Naruse, N; Taguchi, H, 2023) |
| "Alzheimer's disease is a chronic neurodegenerative disease with multiple pathogenesis pathways." | ( Finkelstein, J; Huo, X, 2023) |
| "Alzheimer's disease is one of the most prevalent forms of dementia that occur genetically or sporadically (with increasing age) in the population of 65 years and above." | ( Mishra, S; Raval, M; Tiwari, AK, 2023) |
| "Alzheimer's disease is more prevalent in women, possibly due to sex or growth hormones but existing evidence is inconclusive." | ( Au Yeung, SL; Kwok, MK; Schooling, CM; Yeung, CHC; Zhao, JV, 2023) |
| "Alzheimer's disease is a neurodegenerative disorder that is the leading cause of dementia in elderly patients." | ( Burgos, CF; Castillo, C; F de la Torre, A; Fuentealba, J; Jiménez, CA; López, JJ; Sáez-Orellana, F; Sánchez, Y, 2023) |
| "Alzheimer's disease is a progressive degenerative condition that mainly affects cognition and memory." | ( Ivanova, MI; Kumar, M; Ramamoorthy, A, 2023) |
| "Alzheimer's disease is a most prevalent form of dementia all around the globe and currently poses a significant challenge to the healthcare system." | ( Bedi, PMS; Chadha, R; Kaur, J; Kaur, R; Kaur, U; Sharma, A; Singh, A; Singh, K, 2023) |
| "Alzheimer's disease is the most common type of dementia that currently affects over 6." | ( Ehwerhemuepha, L; Lu, H; Patel, YM; Pierce, A; Rakovski, C; Rezaie, A; Sajjadi, SA; Yaghmaei, E, 2023) |
| "Alzheimer's disease is one of the devastating neurodegenerative diseases affecting mankind worldwide with advancing age mainly above 65 years and above causing great misery of life." | ( Bryukhovetskiy, I; Buzoianu, AD; Feng, L; Lafuente, JV; Manzhulo, I; Muresanu, DF; Nozari, A; Sharma, A; Sharma, HS; Tian, ZR; Wiklund, L, 2023) |
| "Alzheimer's disease is the most frequent neurodegenerative illness in the long run." | ( Karwasra, R; Thakur, R; Umar, T, 2023) |
| "Alzheimer's disease is a progressive neurodegenerative disease and is the most common cause of dementia." | ( Matsubara, T; Miyamoto, E; Sato, T, 2023) |
| Excerpt | Reference |
|---|
| "Eight patients with Alzheimer's disease presenting whith memory difficulties and no significant intellectual deterioration were treated with 9 grams daily." | ( Agid, Y; Lhermitte, F; Signoret, JL; Whiteley, A, 1979) |
| "A patient with Alzheimer's disease and mild features of parkinsonism was treated with tacrine." | ( Lannon, MC; Ott, BR, 1992) |
| "Patients receiving THA for treatment of Alzheimer's disease need regular monitoring of liver function." | ( Ames, DJ; Bhathal, PS; Davies, BM; Fraser, JR; Gibson, PR; Roberts, S, 1990) |
| "Seven women with senile dementia-Alzheimer's type (SDAT) were treated with conjugated estrogen [main content: estrone sulfate (E1-S)], at a dose of 1." | ( Honjo, H; Ishihara, S; Kitawaki, J; Naitoh, K; Ogino, Y; Okada, H; Urabe, M; Yamamoto, T; Yasuda, J; Yonezawa, T, 1989) |
| "Eleven patients with presenile Alzheimer type dementia (ATD) were treated with N-terminal ACTH fragments for 14 days." | ( Bono, G; Facchinetti, F; Genazzani, AR; Martignoni, E; Nappi, G; Petraglia, F; Sinforiani, E, 1988) |
| "Treatment of Alzheimer's disease is currently being investigated using intraventricular bethanechol." | ( Penn, RD, 1985) |
| "Neurotransmitter replacement therapy in Alzheimer's Disease is currently being attempted using bethanechol chloride (Urecholine) infused intracerebroventricularly with an Infusaid continuous infusion pump." | ( Beaulieu, M; Bouchard, R; Carlsson, G; Dastoor, D; Ervin, F; Gauthier, L; Gauthier, S; Leblanc, R; Quirion, R; Robitaille, Y, 1986) |
| "Two agitated patients with Alzheimer's disease who either failed to respond or worsened with conventional low-dose neuroleptic and other pharmacologic treatment are described." | ( Cubberley, L; Lampe, TH; Risse, SC, 1987) |
| "The authors describe five patients with senile dementia of the Alzheimer type (SDAT) who were treated with oral physostigmine from 1 to 3 3/4 years." | ( Beller, SA; Overall, JE; Rhoades, HM; Swann, AC, 1988) |
| "Forty-four patients with senile dementia of the Alzheimer type were randomly allocated into double-blind treatment with either aniracetam (RO 13-5057) 1 g or placebo daily for 3 months." | ( Lahdes, A; Mölsä, P; Portin, R; Rinne, UK; Sourander, LB, 1987) |
| "Ten patients with Alzheimer's disease were treated with intravenous infusion of physostigmine for 2 h." | ( Dahlgren, N; Edvinsson, L; Fernö, H; Gustafson, L; Hagberg, B; Risberg, J; Rosén, I, 1987) |
| "Patients with senile dementia could possibly be benefited by the administration of 5-methyltetrahydrofolate." | ( Barford, PA; Blair, JA; Hamon, CG, 1986) |
| "Ten patients with mild to severe Alzheimer's disease were treated for up to 10 months with 10 to 15 mg oral physostigmine daily or with placebo, according to a single blind, multiple crossover protocol." | ( Jotkowitz, S, 1983) |
| "The increasing prevalence of senile dementia has renewed interest in discovering more effective drug treatments for this condition." | ( Hollister, LE; Yesavage, J, 1984) |
| "No specific treatment is available for Alzheimer's disease." | ( Kokmen, E, 1984) |
| "Eight patients affected by Alzheimer's Presenile Dementia (AD) received acute administration of physostigmine individual optimal dose per os (n = 4) or subcutaneously (n = 4)." | ( Albanese, A; Caltagirone, C; Gainotti, G; Masullo, C, 1983) |
| "Therapeutic trials activity in Alzheimer's disease increased during the past year, with both the initiation of new and the continuation of ongoing symptomatic treatment studies designed to demonstrate enhancement of cognitive abilities." | ( Voci, J; Whitehouse, PJ, 1995) |
| "Patients with Alzheimer's disease received 150 mg/day and 225 mg/day Velnacrine maleate (parallel-group treatment) and placebo." | ( Clipp, EC; Moore, MJ, 1995) |
| "Three patients with Alzheimer's disease of mild type received long-term treatment with THA at doses between 40 mg to 160 mg daily." | ( Nordberg, A; Persson, A; Shigeta, M; Viitanen, M; Winblad, B, 1993) |
| "Seventy-nine patients with probable Alzheimer's disease were enrolled into a double-blind, placebo-controlled cross-over study to assess the therapeutic effect and safety of THA (tetrahydroaminoacridine; tacrine) without concomitant lecithin administration." | ( Boyle, M; Mulligan, K; Neubauer, KA; O'Neill, D; Royston, VH; Scott, M; Surmon, DJ; Wilcock, GK, 1993) |
| "Effective symptomatic treatment of Alzheimer's disease (AD) may require a combination of agents that augment cholinergic as well as noradrenergic neurotransmission." | ( Aisen, PS; Bierer, LM; Davidson, M; Davis, KL; Ryan, TM; Schmeidler, J; Stern, RG, 1993) |
| "Patients with probable Alzheimer's disease (NINCDS criteria) who were randomized in a 30-week double-blind, placebo-controlled, parallel-group, high-dose study of tacrine (1) were subsequently allowed to receive long-term, open-label treatment during which they could receive doses up to 160 mg/day." | ( Gracon, S; Smith, F; Srirama, M; Talwalker, S, 1996) |
| "Standard treatment for Alzheimer's disease involves counseling and support, as well as consideration of tacrine, a cholinergic agent that may stabilize the course in some patients." | ( Filley, CM, 1997) |
| "Developing treatment guidelines for Alzheimer's disease and other dementias depends primarily on a literature review." | ( Rabins, PV, 1996) |
| "Lithium also blocks the Alzheimer's disease-like proline-directed hyperphosphorylation of tau protein which is observed in neurons treated with a phosphatase inhibitor." | ( Avila, J; Diaz-Nido, J; Moreno, FJ; Muñoz-Montaño, JR, 1997) |
| "Treatment of Alzheimer's disease with a cholinergic agonist is associated with a decrease in the MRS choline resonance." | ( Bodick, N; Offen, WW; Renshaw, PF; Satlin, A, 1997) |
| "The prospect that Alzheimer's disease is caused by or related to estrogen deficiency, and treatable or even preventable by estrogen replacement therapy, is alluring." | ( Beckmann, CR, 1997) |
| "Efficacy, assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating-Sum of the Boxes (CDR-SB), was examined in comparison with published data of untreated AD patients." | ( Friedhoff, LT; Rogers, SL, 1998) |
| "Cortisol levels of 30 patients with Alzheimer's disease and 17 healthy elderly subjects were measured before and after administration of dexamethasone." | ( Bruce, I; Buggy, F; Coakley, D; Coen, RF; Kirby, M; Lawlor, BA; Swanwick, GR, 1998) |
| "Patients were administered the Alzheimer's Disease Assessment Scale (ADAS) and Folstein Mini-Mental State Examination (MMSE) at approximately 6-month intervals." | ( Kennedy, Q; Mauricio, M; Miller, TP; Rogerson, S; Schatzberg, A; Taylor, J; Tinklenberg, J; Yesavage, J, 1998) |
| "Current treatment approaches in Alzheimer's disease are primarily symptomatic, with the major therapeutic strategy based on acetylcholinesterase inhibition." | ( Corey-Bloom, J; Grundman, M; Thal, LJ, 1998) |
| "As palliative treatments for Alzheimer's disease proliferate, the focus of therapeutics turns to drugs with the potential to alter course." | ( Davis, KL, 1998) |
| "Differentiation of Alzheimer's disease from vascular dementia has become therapeutically important, since the choice of treatments depends on the diagnosis." | ( Sloane, PD, 1998) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | ( Lacomblez, L, 1998) |
| "With an increased public awareness of Alzheimer's disease (AD), the last two decades have witnessed an immense research effort directed towards discovering the cause of AD with the ultimate hope of developing safe and effective pharmacological treatments." | ( Sirviö, J, 1999) |
| "Because Alzheimer's disease is a heterogeneous disorder, the range of treatment responses likely will remain variable." | ( Larson, EB; Shadlen, MF, 1999) |
| "Understanding the pathogenesis of Alzheimer's disease is of widespread interest because it is an increasingly prevalent disorder that is progressive, fatal, and currently untreatable." | ( Grammas, P; Moore, P; Weigel, PH, 1999) |
| "These two groups of Alzheimer's disease patients performed equally in measures of attention after placebo or clonidine administration." | ( Jäkälä, P; Laakso, MP; Riekkinen, M, 1999) |
| "Distinguishing Alzheimer's disease from DLB is clinically relevant in terms of prognosis and appropriate treatment." | ( Ballard, C; Burn, D; Court, JA; Jaros, E; Johnson, M; Lloyd, S; Marshall, EF; McKeith, IG; Perry, EK; Perry, RH; Piggott, MA; Thomas, N, 1999) |
| "Change in Alzheimer's Disease Assessment Scale cognitive subscale scores from the beginning to the end of the two 6-week treatment periods." | ( Brown, LB; Corwin, C; Daffner, KR; Friedman, P; Gomez-Isla, T; Greenberg, SM; Growdon, JH; Hayden, DL; Meadows, ME; Schoenfeld, DA; Sperling, RA; Tennis, MK; Walsh, KL, 2000) |
| "The extent of activation in Alzheimer's disease is considered to reflect the integrity of synaptic function, or inherent viability, and the potential responsiveness of the Alzheimer brain to drug therapy." | ( Alexander, GE; Dani, A; Furey, ML; Guazzelli, M; Horwitz, B; Mentis, MJ; Pietrini, P; Rapoport, SI; Shapiro, MB, 2000) |
| "Efficacy was assessed using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia Rating-Sum of the Boxes scale (CDR-SB), and data were compared with those predicted for historical untreated AD patients." | ( Doody, RS; Ieni, JR; Pratt, RD; Rogers, SL, 2000) |
| "Among 94 patients with probable Alzheimer's disease who we treated with donepezil, seven patients developed urinary incontinence, although this event was transient in most patients." | ( Hashimoto, M; Imamura, T; Kazui, H; Mori, E; Tanimukai, S, 2000) |
| "Galantamine, a novel treatment for Alzheimer's disease (AD), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase." | ( Lilienfeld, S; Parys, W, 2000) |
| "16 patients with Alzheimer's disease were treated with akatinol memantine." | ( Androsova, LV; Selezneva, ND, 2000) |
| "Early diagnosis in Alzheimer's disease (AD) is important for the administration of new treatments." | ( Capa, G; Durak, H; Ertay, T; Fadiloglu, S; Keskin, B; Sayit, E; Yener, G, 2000) |
| "The treatment of Alzheimer's disease attempts to correct cholinergic deficiency in the brain." | ( Korczyn, AD, 2000) |
| "The efficacy of GAL administered to Alzheimer's disease (AD) patients has been well demonstrated by large-scale clinical trials." | ( Cutler, NR; Frackiewicz, EJ; Sramek, JJ, 2000) |
| "Comprehensive Alzheimer's disease (AD) treatment should address caregiver well-being." | ( Brooks, RL; Fillit, HM; Gutterman, EM, 2000) |
| "Comprehensive treatment of Alzheimer's disease (AD) requires thorough caregiver support and a thoughtful and informed use of medications for cognition enhancement, neuroprotection, and the treatment of disturbed behavior." | ( Reichman, WE, 2000) |
| "Galantamine is a novel treatment for Alzheimer's disease that inhibits acetylcholinesterase and modulates nicotinic receptors." | ( Coyle, J; Kershaw, P, 2001) |
| "Elderly patients with Alzheimer's disease (AD) commonly exhibit psychotic symptoms, prompting clinicians to administer antipsychotics." | ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001) |
| "Benefits on Alzheimer's Disease Assessment Scale-cognitive subscale scores for patients who received 10 mg/d in the double-blind study were evident compared with the other groups for 108 weeks of open-label treatment." | ( Doody, RS; Geldmacher, DS; Gordon, B; Perdomo, CA; Pratt, RD, 2001) |
| "The inflammatory hypothesis of Alzheimer's disease (AD), which is supported both by basic laboratory evidence and epidemiological studies, suggests that treatment with anti-inflammatory drugs may reduce the risk or slow the progression of AD." | ( Aisen, PS, 2000) |
| "(2) PARTICIPANTS: people diagnosed with Alzheimer's disease who meet the criteria for treatment with donepezil, rivastigmine and galantamine." | ( Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N, 2001) |
| "The arrival of these new treatments for Alzheimer's disease has focused attention on the management of dementia in general and has provided the catalyst for the widespread development of memory clinics to enable proper assessment of patients with dementing disorders, providing hope for both patients and carers." | ( Wilkinson, D, 2001) |
| "Current treatment of Alzheimer's Disease (AD) requires acetylcholinesterase inhibition to increase acetylcholine (ACh) concentrations in the synaptic cleft." | ( Billard, W; Binch, H; Clader, J; Coffin, V; Cohen-Williams, M; Crosby, G; Duffy, RA; Kozlowski, J; Lachowicz, JE; Ruperto, V; Strader, CD; Zhou, G, 2001) |
| "Using lessons learned from Alzheimer's disease research, it has been proposed that enhancement of the cholinergic system is a rational approach to treating the symptoms of VaD." | ( Maelicke, A, 2001) |
| "twenty patients with Alzheimer's disease and 23 elderly control subjects, living at home, free from disease and not undergoing any treatment known to have a strong influence on blood oxidative stress markers or antioxidant defence systems." | ( Bourdel-Marchasson, I; Decamps, A; Delmas-Beauvieux, MC; Emeriau, JP; Peuchant, E; Rainfray, M; Reignier, B; Richard-Harston, S, 2001) |
| "An 83-year-old woman with a history of Alzheimer's disease and breast cancer died at home while receiving palliative pain therapy with oral morphine from her family for metastatic breast cancer." | ( King, T; Levine, B; Pestaner, JP; Smialek, JE, 2001) |
| "Depressive symptoms of patients with Alzheimer's disease (AD) and aged non-Alzheimer patients may also respond to treatment with EGb 761 since this extract has an "anti-stress" effect." | ( DeFeudis, FV; Drieu, K, 2000) |
| "The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue." | ( Duttagupta, S; Fillit, HM; Knopman, DS; Lloyd, JR; Max, W; Rice, DP, 2001) |
| "The Assessment of Health Economics in Alzheimer's Disease (AHEAD) model, which uses algorithms to predict the time until patients with AD require full-time care (FTC), was adapted to Canada to compare treatment with galantamine versus no pharmacologic treatment." | ( Caro, G; Caro, JJ; Getsios, D; Ishak, K, 2001) |
| "During the last years, treatment of Alzheimer's disease has improved following a better detection of this disease and, more importantly, following a better knowledge of its physiopathogeny." | ( Sternon, J; Ventura, M, 2001) |
| "Data were collected from patients with Alzheimer's disease who were treated with rivastigmine between 1 October 1998-30 November 1999 at the Memory Disorders Outpatients Clinic at the Academic Medical Centre or the Slotervaart Hospital, both in Amsterdam, the Netherlands." | ( Richard, E; van Campen, J; van Gool, WA; Vissers, E; Walstra, GJ, 2002) |
| "Thirteen patients with Alzheimer's disease (AD), 6 receiving treatment with the cholinesterase inhibitor, tacrine [tetrahydroaminoacridine (THA)], and 7 receiving no treatment, were administered 2 mg of nicotine polacrilex and placebo." | ( Engeland, C; Ilivitsky, V; Knott, VJ; Mahoney, C; Mohr, E, 2002) |
| "Understanding of the pathogeny of Alzheimer's disease and, consequently, of ways to its therapy is still quite limited, in spite of enormous effort by investigators." | ( Dolezal, V; Kasparová, J, 2002) |
| "Because Alzheimer's disease impairs memory, and infusion of amyloid-beta (Abeta) peptide (1-40) into the rat cerebral ventricle reduces learning ability, we investigated the effect of dietary pre-administration of docosahexaenoic acid on avoidance learning ability in Abeta peptide-produced Alzheimer's disease model rats." | ( Fujii, Y; Hashimoto, M; Hossain, S; Ishibashi, Y; Oka, J; Shido, O; Shimada, T; Sugioka, K; Yamasaki, H, 2002) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| "We found that fibroblasts from Alzheimer's disease patients were more resistant that those from control subjects to H(2)O(2) treatment, although the extent of DNA damage induced by the oxidative injury was similar in both experimental groups." | ( Bernardi, E; Carsana, T; Govoni, S; Grigolato, P; Lanni, C; Memo, M; Racchi, M; Rodella, L; Uberti, D, 2002) |
| "To reconstitute an Alzheimer's disease model by administering bradykinin (BK) or cyclosporine A (CSA) to the rat hippocampus." | ( Wang, J; Wang, Q, 2002) |
| "In the absence of a cure for Alzheimer's disease (AD), treatment has focused on therapy to provide symptomatic benefits and to slow progression of the disease, so that patients can maintain their independence for as long as possible." | ( Farlow, MR, 2002) |
| "The Assessment of Health Economics in Alzheimer's Disease (AHEAD) model compares galantamine treatment with no pharmacologic treatment." | ( Caro, JJ; Garfield, FB; Getsios, D; Wimo, A; Winblad, B, 2002) |
| "To understand the treatment goals of Alzheimer's disease (AD) patients, carers, and physicians; to estimate whether clinically important goals are met during treatment with donepezil; and to compare a measure of goal attainment with standard measures used to evaluate AD treatment." | ( Fay, S; Graham, JE; Rockwood, K, 2002) |
| "A 75-years-old man with Alzheimer's disease, treated with the cholinesterase inhibitor donepezil for 14 months, was scheduled for left colectomy under general anesthesia." | ( Demartini Ferrari, A; Roca de Togores López, A; Sánchez Morillo, J, 2003) |
| "Currently the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) is largely unrealised, with no preventive or curative therapies." | ( Maubach, K, 2003) |
| "Current treatments for Alzheimer's disease focus on deficits in the cholinergic neurochemical pathway." | ( Mintzer, JE, 2003) |
| "Approved treatments for Alzheimer's disease have focused primarily on cholinergic enhancement." | ( Sano, M, 2003) |
| "Patients who had Alzheimer's disease with cerebrovascular disease continuously treated with galantamine maintained the cognitive abilities seen at baseline for at least 12 months." | ( Erkinjuntti, T; Kurz, A; Lilienfeld, S; Small, G, 2003) |
| "RATIONALE IN ALZHEIMER'S DISEASE: Selective serotonine uptake inhibitors (SSRI) have demonstrated their effectiveness for symptomatic treatment of depression, as well as for behavioral and psychological disorders in dementia patients, particularly in Alzheimer's disease." | ( Lebert, F, 2003) |
| "Early diagnosis of Alzheimer's disease (AD) is needed to initiate symptomatic treatment with acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at slowing down the degenerative process, such as vaccination regimes and beta-secretase and gamma-secretase inhibitors, prove to affect AD pathology and to have clinical effect." | ( Blennow, K; Hampel, H, 2003) |
| "Among patients with moderate Alzheimer's disease, caregivers of galantamine-treated patients were even more likely to report reductions (46% vs 37%), maintenance (15% vs 6%) or smaller increases (25% vs 42% for increases >30 min) vs placebo (p=0." | ( Kavanagh, S; Sano, M; van Baelen, B; Wilcock, GK, 2003) |
| "Current treatment of Alzheimer's disease (AD) has focused on the use of cholinesterase inhibitors." | ( Doraiswamy, PM, 2003) |
| "Mean Alzheimer's Disease Assessment Scale cognitive subscale scores were improved after treatment with donepezil, relative to placebo, at weeks 6, 12, 18, and 24." | ( Charles, HC; Doraiswamy, PM; Ieni, JR; Krishnan, KR; Mintzer, J; Perdomo, C; Rogers, S; Weisler, R; Yu, X, 2003) |
| "Subjects with Alzheimer's disease and nighttime sleep disturbance were randomly assigned to 1 of 3 treatment groups: placebo, 2." | ( Gamst, A; Grundman, M; Kaye, J; Schafer, K; Singer, C; Thal, LJ; Thomas, R; Tractenberg, RE, 2003) |
| "A study was performed on patients with Alzheimer's disease (AD) in order to evaluate the efficacy of a combined treatment (donepezil plus cognitive training) in both cognitive processes and affective states." | ( Campo, P; López Ibor, JJ; López Ibor, MI; Maestú, F; Ortiz, T; Requena, C, 2004) |
| "The cholinergic denervation in Alzheimer's disease (AD) provides the rationale for treatments with anticholinesterases." | ( Mash, D; Mesulam, M; Shaw, P; Weintraub, S, 2004) |
| "Fifty consecutive outpatients with Alzheimer's disease (AD) received treatment with the cholinesterase inhibitor tacrine in an open longitudinal study." | ( Gustafson, L; Minthon, L; Sjögren, M; Wallin, AK; Wattmo, C, 2004) |
| "Treatment of Alzheimer's disease (AD) that combats progressive functional deterioration can improve the patient's quality of life and reduce caregiver burden." | ( Doody, R; Möbius, HJ; Schmitt, F; Wirth, Y, 2004) |
| "Thirteen patients with probable Alzheimer's disease (AD), 6 receiving treatment with the cholinesterase inhibitor (ChEI) tacrine (tetrahydroaminoacridine, THA) and 7 receiving no treatment, were administered 2 mg of nicotine polacrilex and placebo." | ( Engeland, C; Ilivitsky, V; Knott, V; Mahoney, C; Mohr, E, 2002) |
| "For each category of Alzheimer's disease patient examined, treatment with memantine was a cost-effective strategy." | ( Guilhaume, C; Jones, RW; McCrone, P, 2004) |
| "At present, the therapy of Alzheimer's disease is aimed at improving both, cognitive and behavioural symptoms and thereby, quality of life for the patients." | ( Kaul, CL; Ramarao, P; Sonkusare, SK, 2005) |
| "Statins hold promise in therapy of Alzheimer's disease, but the current data are more consistent with a model of statins that act as neuroprotective agents rather than inhibitors of beta-amyloid production." | ( Wolozin, B, 2004) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "To characterise the population of Alzheimer's disease patients treated with acetylcholinesterase inhibitors, to analyse effectiveness and drug safety in the clinical practice, and to identify variables that may predict the response to therapy." | ( Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N, 2005) |
| "Although FDA-approved Alzheimer's disease (AD) treatment strategies (cholinesterase inhibitors and memantine) offer proven benefits, providers recognize unmet needs beyond what is currently available." | ( Doraiswamy, PM; Xiong, G, 2005) |
| "Comorbid depression of Alzheimer's disease (AD) is a common mood disorder in the elderly and a broad spectrum of antidepressants have been used for its treatment." | ( Bjelik, A; Hugyecz, M; Janka, Z; Kálmán, J; Kása, P; Pákáski, M, 2005) |
| "In this study 11 patients with mild Alzheimer's disease (AD) were treated with the cholinesterase inhibitor rivastigmine (mean dose 8." | ( Almkvist, O; Forsberg, A; Långström, B; Nilsson, A; Nordberg, A; Stefanova, E; Wall, A, 2006) |
| "Treatment of Alzheimer's disease (AD) with cholinesterase inhibitors carries a theoretical risk of precipitating bradycardia." | ( Bordier, P; Garrigue, S; Gencel, L; Lafitte, A; Lanusse, S; Reynard, C; Robert, F, 2005) |
| "Pharmacological therapy in Alzheimer's disease." | ( Schölzel-Dorenbos, CJ, 2005) |
| "Pharmacological treatment of Alzheimer's disease focuses on correcting the cholinergic deficiency in the central nervous system with cholinesterase inhibitors." | ( Beck-Bornholdt, HP; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T, 2005) |
| "Early and continued treatment of Alzheimer's disease with rivastigmine maximizes the observed beneficial effects." | ( Desai, AK; Grossberg, GT, 2005) |
| "The cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) was a primary endpoint in both trials, and in both trials a statistically significant difference was seen between treatment groups after 28 weeks." | ( Möbius, HJ; Stöffler, A, 2003) |
| "Similarly for the Alzheimer's Disease Assessment Scale--Cognition (treatment group mean change +0." | ( Bartorelli, L; Bernabei, R; Carbone, G; Frisoni, GB; Giacobini, E; Lambertucci, P; Onder, G; Silveri, MC; Zanetti, O, 2005) |
| "Thirteen patients with mild Alzheimer's disease treated with rivastigmine 6-12 mg/day for more than two months started cognitive rehabilitation training." | ( Alvarez, AM; Andrade, FC; Avila, R; Bottino, CM; Bustamante, SE; Câmargo, CH; Carvalho, IA; Hototian, SR; Saffi, F; Zukauskas, PR, 2005) |
| "The high prevalence rates of both Alzheimer's disease (AD) and type 2 diabetes mellitus in the elderly population suggest that concomitant pharmacotherapy is likely." | ( Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005) |
| "Current pharmacotherapy for Alzheimer's disease involves compounds that are aimed at increasing the levels of acetylcholine in the brain by facilitating cholinergic neurotransmission through inhibition of cholinesterase." | ( Castro, A; Martinez, A, 2006) |
| "Managing Alzheimer's disease (AD) continues to challenge long-term care physicians and administrators." | ( Bright-Long, L, 2006) |
| "Delays in the diagnosis of Alzheimer's disease, and, therefore, delays in treatment, may have a detrimental effect on a patient's long-term well-being." | ( Engedal, K; Haglund, A; Schindler, R; Soininen, H; Verhey, F; Waldemar, G; Wetterholm, AL; Wimo, A; Winblad, B; Zhang, R, 2006) |
| "Patients with mild to moderate Alzheimer's disease received open-label treatment with donepezil (5 mg/day for 4 weeks, then 10 mg/day for the remainder of the phase) for 12-24 weeks." | ( Hampel, H; Johannsen, P; Qvitzau, S; Richardson, S; Salmon, E; Schindler, R; Xu, Y, 2006) |
| "The search for effective treatments of Alzheimer's disease (AD) is one of the major challenges facing modern medicine." | ( Geerts, H; Grossberg, GT, 2006) |
| "An 82 year old patient with Alzheimer's disease (AD) developed complete atrioventricular block and ventricular tachyarrhythmia 1 month after starting treatment with donepezil, and was admitted to the emergency department because of dizziness and syncope." | ( Abdulkadir, G; Ozlem, S; Suleyman, T; Tevfik, P, 2006) |
| "treat Alzheimer's disease." | ( Brinton, RD; Chen, S; Nilsen, J, 2006) |
| "Specific treatments for Alzheimer's disease (AD) were first introduced in the 1990s using the acetyl-cholinesterase inhibitors." | ( Dean, RA; Demattos, R; May, PC; Siemers, ER, 2006) |
| "People with Alzheimer's disease are administered fewer analgesics and report less clinical pain than cognitively intact peers with similar painful diseases or injuries, prompting speculation about the likely impact of neurodegeneration on central pain processing." | ( Barber, JB; Cole, LJ; Duff, EP; Egan, GF; Farrell, MJ; Gibson, SJ, 2006) |
| "A total of 10 subjects with Alzheimer's disease (AD) of mild severity underwent high resolution split-dose single photon emission computed tomography (SPECT) during performance of a verbal recognition and control task, both before and after 18 weeks treatment with melameline or placebo." | ( Brodaty, H; Haindl, W; Sachdev, PS; Trollor, JN; Walker, BM; Wen, W, 2006) |
| "Cholesterol metabolism is involved in Alzheimer's disease (AD) pathogenesis: increased cholesterol blood levels are detected in AD patients, and treatment with statins reduces the risk of AD." | ( Heun, R; Holzapfel, J; Jessen, F; Kölsch, H; Lütjohann, D; Maier, W, 2006) |
| "Treatment of Alzheimer's disease (AD) is difficult due to ignorance of its pathogenesis." | ( Badmaev, V; Bernard, G; Cashman, J; Espinosa, A; Fiala, M; Graves, MC; Mahanian, M; Rosenthal, M; Sayre, J; Zaghi, J; Zhang, L, 2006) |
| "In this retrospective analysis, Alzheimer's disease patients younger than 75 with wild-type BuChE exhibited differential efficacy to rivastigmine, while BuChE K-variant carriers experienced similar long-term treatment effects with both agents." | ( Bergman, H; Blesa, R; Bullock, R; Gambina, G; He, Y; Lane, R; Meyer, J; Nagel, J; Rapatz, G, 2006) |
| "Previous studies in Alzheimer's Disease (AD) suggest a benefit from switching from one cholinesterase (ChE) inhibitor to another in the event of treatment failure on the index agent." | ( Gauthier, S; Juby, A; Morelli, L; Rehel, B; Schecter, R, 2006) |
| "Amyloid beta (Abeta) immunotherapy for Alzheimer's disease has shown initial success in mouse models of Alzheimer's disease and in human patients." | ( Bigio, EH; Chang, L; De Felice, FG; Fernandez, S; Gong, Y; Khuon, D; Klein, WL; Krafft, GA; Lacor, PN; Lambert, MP; Shaw, P; Velasco, PT; Viola, KL, 2007) |
| "To date, the primary treatments for Alzheimer's disease with proven efficacy have been acetylcholinesterase inhibitors that prevent the hydrolysis of acetylcholine (ACh) in the synaptic cleft, thereby prolonging its activity." | ( Bencherif, M; Gatto, GJ; Letchworth, SR; Lippiello, P; Traina, VM, 2006) |
| "The in vitro model of Alzheimer's disease was constructed with A beta42-treated PC12 cells." | ( Chen, Z; Dai, HB; Fu, QL; Shen, Y, 2007) |
| "Galantamine, a drug used to treat Alzheimer's disease, is a nicotinic allosteric potentiating ligand, and kynurenic acid (KYNA), a neuroactive metabolite of the kynurenine pathway, is an endogenous noncompetitive inhibitor of alpha7* nicotinic receptors (nAChRs) [the asterisk next to the nAChR subunit is intended to indicate that the exact subunit composition of the receptor is not known (Pharmacol Rev 51:397-401, 1999)]." | ( Albuquerque, EX; Lopes, C; Njar, V; Pereira, EF; Purushottamachar, P; Schwarcz, R; Wu, HQ, 2007) |
| "Many potential treatments for Alzheimer's disease target amyloid-beta peptides (Abeta), which are widely presumed to cause the disease." | ( Cheng, IH; Gerstein, H; Mucke, L; Palop, JJ; Roberson, ED; Scearce-Levie, K; Wu, T; Yan, F; Yu, GQ, 2007) |
| "While, as in Alzheimer's disease, cholinergic dysfunction has long been identified to be related to the cognitive impairment in Parkinson's dementia, the fear of exacerbating the motor symptoms of the disorder has greatly hindered research into the anticholinesterases as symptomatic treatments for the cognitive and psychiatric deficits." | ( Wesnes, K, 2007) |
| "Biometals have an important role in AD (Alzheimer's disease) and metal ligands have been investigated as potential therapeutic agents for treatment of AD." | ( Barnham, KJ; Caragounis, A; Cherny, RA; Crouch, PJ; Drew, SC; Du, T; Filiz, G; Hill, AF; Laughton, KM; Li, QX; Masters, CL; Sharples, RA; Volitakis, I; White, AR, 2007) |
| "The discovery of cholinergic deficit in Alzheimer's disease (AD) patient's brain has triggered research efforts, using cholinomimetic approaches for their efficacy in AD therapy." | ( Chandra, JN; Malviya, M; Rangappa, KS; Sadashiva, CT; Subhash, MN, 2008) |
| "Treating elderly patients with Alzheimer's disease (AD) and behavioral and psychological symptoms of dementia (BPSD) is challenging due to the increased risk of iatrogenic movement disorders with old neuroleptics and the seemingly increasing risk of cardiovascular events with newer atypical agents." | ( Barak, Y; Mazeh, D; Mirecky, I; Paleacu, D, 2008) |
| "In the treatment of Alzheimer's disease tacrine, a cholinesterase inhibitor, is not the drug of choice due to its low oral bioavailability, extensive hepatic first-pass effect, rapid clearance from the systemic circulation, pronounced hepatotoxicity, and the availability of drugs better than tacrine in the same pharmacological class." | ( Jogani, VV; Mishra, AK; Mishra, P; Misra, AR; Shah, PJ, 2007) |
| "We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks." | ( Ballard, CG; Bentham, P; Brown, RG; Bullock, R; Burns, AS; DeCesare, J; Holmes, C; Howard, RJ; Jacoby, R; Johnson, T; Jones, RW; Juszczak, E; Katona, C; Knapp, M; Lindesay, J; O'Brien, JT; Rodger, M; Wilcock, G, 2007) |
| "Patients had probable Alzheimer's disease and received treatment with memantine for at least one month." | ( Boustani, M; Brown, RC; Fox, CG; Katona, CL; Maidment, ID; Rodriguez, J, 2008) |
| "Patients with Alzheimer's disease (n = 117) and schizophrenia (n = 406) were treated with olanzapine as part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)." | ( Aravagiri, M; Bies, RR; Bigos, KL; Coley, KC; Kirshner, MA; Marder, SR; Miller, DD; Pollock, BG; Schneider, LS, 2008) |
| "Female Alzheimer's disease mice treated with oxybutynin but not males showed improved behavior with a greater percent of time spent in the closed arm or elevated plus maze (95." | ( Fletcher, S; Klausner, AP; Neff, P; Sharma, S; Son, H; Steers, WD; Tuttle, JB; Yang, SK, 2008) |
| "To describe a cohort of patients with Alzheimer's disease from a whole city population treated with donepezil, and to analyse outcomes over 4 years." | ( Benbow, S; Clark, M; Grizzell, M; Jolley, D; Lyle, S; Willmott, S, 2008) |
| "In order to advance the treatment of Alzheimer's disease with active ingredients of Chinese herbal medicines and the research on these ingredients and their effective targets in treating the disease, the relative representative literatures published in recent years were reviewed and summarized in this paper." | ( Wang, DS; Zhao, JK, 2008) |
| "A blood-based biomarker of Alzheimer's disease (AD) progression could be instrumental in targeting asymptomatic individuals for treatment early in the disease process." | ( Bandaru, VV; Carlson, MC; Haughey, NJ; Lyketsos, CG; Mielke, MM; Rabins, PV, 2010) |
| "Rivastigmine-treated Alzheimer's disease patients who had been maintained on a fixed regimen of twice-daily rivastigmine for >or=2 months were eligible to enter the study." | ( Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J, 2008) |
| "Although treatments for Alzheimer's disease sometimes improve cognition, functional ability, or behaviour compared with baseline levels, such improvements are inconsistent across studies and measures, and effects diminish over time." | ( Aisen, PS; Bachurin, SO; Doody, RS; Gavrilova, SI; Hung, D; Sano, M; Seely, L; Thomas, RG, 2008) |
| "Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine." | ( Gartlehner, G; Hansen, RA; Jonas, DE; Moore, CG; Morgan, LC; Webb, AP, 2008) |
| "Treatment of Alzheimer's disease (AD) and the discovery of promising drug candidates depend on early diagnosis." | ( Alkon, DL; Khan, TK, 2010) |
| "Current treatments for Alzheimer's disease aim to compensate for biochemical deficits in the brain." | ( Allali, G; De Souza, L; Dubois, B; Kalafat, M; Sarazin, M, 2008) |
| "Some of the implications are that Alzheimer's disease and other diseases of neurodegeneration and fibrotic, inflammatory, and autoimmune diseases may be treatable by lowering the availability of free copper." | ( Brewer, GJ, 2008) |
| "Studies on Alzheimer's disease and Lewy body dementias show that cholinesterase inhibitors are still first line treatment for these diseases and memantine is indicated in moderate/severe Alzheimer's disease, whereas there is as yet no standard available treatment for frontotemporal dementias." | ( Engelhardt, E; Laks, J, 2008) |
| "Forty-one patients with Alzheimer's disease (AD) were treated with donepezil at baseline." | ( Fukui, T; Furukawa, TA; Hongo, J; Iidaka, T; Mimura, M; Murata, Y; Nakaaki, S; Sato, J; Shinagawa, Y; Soma, T; Tatsumi, H; Tohyama, J, 2008) |
| "While Alzheimer's disease (AD) represents a major healthcare challenge, with 25 to 34 million individuals currently affected worldwide and triple this number of patients projected by 2050, the drugs currently approved for the palliative treatment of AD, the cholinesterase inhibitors and the NMDA antagonist memantine, have demonstrated questionable efficacy, highlighting an urgent need for new therapies." | ( Williams, M, 2009) |
| "Seven probable Alzheimer's disease patients and seven demographically comparable controls underwent two positron emission tomography (PET) glucose metabolism scans, after administration of a saline placebo infusion (Day 1) and after citalopram (40 mg, IV, Day 2)." | ( Chaly, T; Dhawan, V; Eidelberg, D; Hermann, CR; Kramer, E; Ma, Y; Smith, GS, 2009) |
| "Available treatments for Alzheimer's disease (AD) need to be evaluated in order to determine whether the clinical benefits justify their additional costs." | ( García-Pérez, L; Hart, W; Linertová, R; López-Bastida, J, 2009) |
| "For therapies for Alzheimer's disease (AD) to have the greatest impact, it will likely be necessary to treat individuals in the "preclinical" (presymptomatic) stage." | ( Fagan, AM; Head, D; Holtzman, DM; Marcus, D; Mintun, M; Morris, JC; Shah, AR, 2009) |
| "Efficacy outcomes included the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) score and treatment response (ADAS-cog maintenance [>or=0-point improvement], improvement >or=4 points and improvement >or=7 points)." | ( Aronson, S; Kavanagh, S; Schwalen, S; Van Baelen, B, 2009) |
| "Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects." | ( Dagerman, KS; Hsiao, JK; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, C; Zheng, L, 2009) |
| "Today there is no causal therapy for Alzheimer's disease (AD)." | ( Müller-Spahn, F; Sollberger, D; Wollmer, MA, 2009) |
| "A total of 71 patients with mild Alzheimer's disease (Mini-Mental State Examination score > or = 21 and < or = 26) were successfully randomly assigned to placebo (N = 38) or lithium treatment (N = 33) at 6 academic expert memory clinics." | ( Annas, P; Basun, H; Bogstedt, A; Bürger, K; Ewers, M; Frölich, L; Gasser, T; Hampel, H; Kraft, I; Kurz, A; Leyhe, T; Möller, HJ; Mörtberg, A; Riepe, MW; Schönknecht, P; Schröder, J, 2009) |
| "Cognitive improvement in Alzheimer's disease (AD) patients treated with intravenous immunoglobulin (IvIg) has been attributed to its antibodies to amyloid beta (Abeta)." | ( Balasubramaniam, M; Digambaranath, J; Finke, JM; Klaver, AC; Loeffler, DA, 2010) |
| "To estimate the prevalence of Alzheimer's disease (AD) treatment in Aragon (Spain), analyzing differences according to age, gender and health area." | ( Bjerrum, L; Feja, C; Rabanaque, MJ; Villar-Fernández, I, 2009) |
| "Excellent treatment for Alzheimer's disease remains an unmet medical need." | ( Doody, RS, 2009) |
| "Dementia and Alzheimer's disease (AD) are rapidly increasing public health problems in ageing populations and at the moment curative treatment is lacking." | ( Eskelinen, MH; Kivipelto, M, 2010) |
| "To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D-aspartate receptor (NMDAR) antagonist." | ( Bolognesi, ML; Melchiorre, C; Milelli, A; Minarini, A; Rosini, M; Tumiatti, V, 2010) |
| "The use of nicotine for treatment of Alzheimer's disease should be reassessed." | ( Deng, J; Fang, CQ; Gao, CY; Li, J; Shen, C; Wang, YJ; Xu, ZQ; Zhang, M; Zhou, HD, 2010) |
| "Here we show that an early-onset Alzheimer's disease transgenic mouse model expressing the double-mutant form of human amyloid precursor protein (APP); Swedish (K670N/M671L) and Indiana (V717F) undergoing treatment with 17beta-estradiol show significantly lower levels of APP processing through beta-secretase and enhanced alpha-secretase processing resulting in marked reductions of APP-CTFbeta, Abeta42 and plaque burden, along with increased levels of the non-amyloidogenic sAPPalpha." | ( Amtul, Z; Rozmahel, RF; Wang, L; Westaway, D, 2010) |
| "For the primary outcome of modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) scores at 12 weeks of follow-up, the odds of being at or better than a given mADCS-CGIC category did not significantly differ between the two treatment groups for those patients with MaD at baseline (OR(sertraline) = 0." | ( Drye, LT; Frangakis, CE; Lyketsos, CG; Martin, BK; Meinert, CL; Mintzer, JE; Munro, CA; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D, 2011) |
| "Currently approved Alzheimer's disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression." | ( Brand-Schieber, E; Farlow, MR; Hsu, T; Moline, ML; Salloway, S; Satlin, A; Tariot, PN; Wang, Q; Yardley, J; Zou, H, 2010) |
| "In a randomized controlled trial in Alzheimer's disease (AD), we found a higher number of intracerebral hemorrhages (ICHs) in patients randomized to aspirin treatment." | ( Bentham, P; De Haan, RJ; Gray, R; Nederkoorn, PJ; Richard, E; Thoonsen, H; van Geloven, N; Van Gool, WA, 2010) |
| "Older age, longer time between Alzheimer's disease diagnosis and first ChEI dispensing, lower dose of ChEI at treatment initiation and the presence of baseline depression and neuropsychiatric symptoms were associated with a significantly increased likelihood of antipsychotic drug use." | ( Duh, MS; Kahler, KH; Lefebvre, P; Mody-Patel, N; Scharre, DW; Vekeman, F, 2010) |
| "In this retrospective analysis, Alzheimer's disease patients with no prior use of antipsychotics initiated on rivastigmine had a significantly lower rate of prescription of antipsychotic drugs than those treated with donepezil." | ( Duh, MS; Kahler, KH; Lefebvre, P; Mody-Patel, N; Scharre, DW; Vekeman, F, 2010) |
| "At diagnosis, Alzheimer's disease (AD) brains are extensively burdened with plaques and tangles and display a degree of synaptic failure most likely beyond therapeutic treatment." | ( Allard, S; Arvanitis, DN; Canneva, F; Cuello, AC; Ducatenzeiler, A; Ferretti, MT; Glabe, CG; Houle, D; Klein, WL; Leon, WC; Partridge, V; Szyf, M; Vercauteren, F, 2011) |
| "The current drug treatment for Alzheimer's disease (AD) is only partially and temporary effective." | ( Aichenbaum, S; Bentwich, J; Dobronevsky, E; Khaigrekht, M; Marton, RG; Peretz, R; Rabey, JM; Shorer, R, 2011) |
| "The field of Alzheimer's disease (AD) research eagerly awaits the results of a large number of Phase III clinical trials that are underway to investigate the effectiveness of anti-amyloid-β (Aβ) immunotherapy for AD." | ( Beach, TG; Daugs, ID; Hunter, JM; Kokjohn, TA; Maarouf, CL; Roher, AE; Sabbagh, MN, 2011) |
| "The symptomatic treatment of Alzheimer's disease is currently carried out using a twofold therapeutic approach involving acetylcholinesterase inhibitors, whose mechanism of action is based on the selective inhibition of this enzyme, and memantine, which acts by blocking the pathological tonic activation of NMDA receptors." | ( Molinuevo, JL, 2011) |
| "Current treatments for Alzheimer's disease only offer limited symptomatic alleviation, and more effective therapies are needed for Alzheimer's disease." | ( Han, M; Liu, J; Liu, Y; Tan, Q; Wang, W; Wang, YY; Zhang, B; Zhang, JM; Zhang, XJ, 2011) |
| "Diagnosing and treating patients with Alzheimer's disease (AD) at an early stage should improve the quality of life of the patient and caregiver." | ( Blume, S; Getsios, D; Hernández, L; Ishak, KJ; Maclaine, G, 2012) |
| "Hypertension is a major risk factor of Alzheimer's disease (AD); however, controlled studies on the effect of antihypertensive treatment on the risk of dementia are inconclusive." | ( Bergmann, A; Blennow, K; Buerger, K; Ernst, A; Hampel, H; Hansson, O; Hartmann, O; Minthon, L; Moeller, HJ; Rujescu, D; Schneider, P; Teipel, S; Uspenskaya, O; Zetterberg, H, 2011) |
| "The 'preclinical' phase of Alzheimer's disease is a future target for treatment, but additional research is essential to understand the relationship between β-amyloid burden and cognition during this time." | ( Ames, D; Chételat, G; Ellis, KA; Good, N; Laws, SM; Martins, RN; Masters, CL; Pike, KE; Rowe, CC; Szoeke, C; Verdile, G; Villemagne, VL, 2011) |
| "New treatments against Alzheimer's disease (AD) may be just around the corner." | ( Rinne, JO; Scheinin, M; Scheinin, NM, 2011) |
| "Treatment of Alzheimer's disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms." | ( Gröhn, H; Hänninen, T; Jauhiainen, AM; Miettinen, PS; Niskanen, E; Pihlajamäki, M; Soininen, H; Tarkka, IM; Vanninen, R, 2011) |
| "Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment." | ( Adami, M; Bruno, G; Gaudig, M; Jacobs, A; Richarz, U; Scarpini, E; Schäuble, B; Zappalà, G, 2011) |
| "The pathogenesis of Alzheimer's disease (AD) has been strongly associated with the accumulation of amyloid beta (Aβ) peptides in brain, and immunotherapy targeting Aβ provides potential for AD prevention." | ( Anderson, LD; Eagar, TN; Fu, M; Lambracht-Washington, D; Qu, BX; Rosenberg, RN; Stüve, O, 2011) |
| "Treatment of Alzheimer's disease (AD) is plagued by a lack of practical and reliable methods allowing early diagnosis of the disease." | ( Aureliano, CS; Esselmann, H; Schillinger, E; Sellergren, B; Urraca, JL; Wiltfang, J, 2011) |
| "The loss of synapses and neurons in Alzheimer's disease (AD) is thought to be at least partly induced by toxic species formed by the amyloid beta (Aβ) peptide; therefore, therapeutics aimed at reducing Aβ toxicity could be of clinical use for treatment of AD." | ( Bereczki, E; Masserini, ME; Pei, JJ; Re, F; Winblad, B, 2011) |
| "The differential diagnosis of presenile dementia, aetiology and pathogenesis of Hashimoto's encephalomyelitis, and treatment options are discussed." | ( Chong, CS; Leung, JL; Miao, MY; Ng, PW; Wong, IH, 2011) |
| "In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation." | ( Cunqueiro, K; Devanand, DP; Marder, K; Pelton, GH; Sackeim, HA, 2011) |
| "Current treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD." | ( Annweiler, C; Beauchet, O; Fantino, B; Gautier, J; Parot-Schinkel, E; Thiery, S, 2011) |
| "Our data may contribute to both Alzheimer's disease therapy and pain clinics where morphine is widely used." | ( Chai, Z; Cui, J; Dong, Q; Hu, J; Wang, Y; Wu, S; Xiao, X; Zhang, Y, 2011) |
| "We utilized data from the Depression in Alzheimer's Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD." | ( Avramopoulos, D; Dimitri, A; Drye, LT; Frangakis, CE; Lyketsos, CG; Martin, BK; Meinert, CL; Mintzer, J; Munro, CA; Peters, ME; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Vaidya, V; Weintraub, D, 2011) |
| "In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months." | ( Adams, J; Baldwin, A; Ballard, C; Banerjee, S; Barber, R; Bentham, P; Brown, R; Burns, A; Dening, T; Findlay, D; Gray, R; Griffin, M; Hills, R; Holmes, C; Howard, R; Hughes, A; Jacoby, R; Johnson, T; Jones, R; Juszczak, E; Katona, C; Knapp, M; Lindesay, J; Macharouthu, A; McKeith, I; McShane, R; O'Brien, J; Onions, C; Passmore, P; Phillips, P; Ritchie, C; Sheehan, B, 2012) |
| "Current treatment of Alzheimer's disease rests on cholinergic and anti-glutamatergic substances." | ( Neumeister, KL; Riepe, MW, 2012) |
| "To explore the risk of developing Alzheimer's disease (AD) in individuals with diabetes mellitus treated with metformin or other antidiabetic drugs." | ( Bodmer, M; Imfeld, P; Jick, SS; Meier, CR, 2012) |
| "Current Alzheimer's disease interventions are symptomatic treatments with limited efficacy that do not address etiology." | ( Eslami, P; Gabbita, SP; Greig, NH; Harris-White, ME; Johnson, MF; Kobritz, NK; Sharma, SP; Srivastava, MK; Tweedie, D; Zemlan, FP, 2012) |
| "In a mouse model of Alzheimer's disease (AD) the orally administered natural product 4'-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by inhibiting neuroinflammation." | ( Anavi-Goffer, S; Gertsch, J, 2012) |
| "Among the dementias, Alzheimer's disease (AD) is the most commonly diagnosed, but there are still no effective drugs available for its treatment." | ( Adlard, PA; Bush, AI; Carrasco, J; Comes, G; Hidalgo, J; Manso, Y; Meloni, G; Vašák, M, 2012) |
| "Donepezil used for the treatment of Alzheimer's disease inhibits decomposition of acetylcholine." | ( Pautola, L; Reinikainen, M, 2012) |
| "Beside toxins, drugs for treatment of Alzheimer's disease and myasthenia gravis, such as galantamine, donepezil, rivastigmine, tacrine, huperzine, pyridostigmine and neostigmine, are known." | ( Pohanka, M, 2012) |
| "The treatment of Alzheimer's disease and many other brain-related disorders is limited because of the presence of the blood-brain barrier, which highly regulate the crossing of drugs." | ( Araya, E; Egea, G; Giralt, E; Guerrero, S; Kogan, MJ; López-Iglesias, C; Molina, C; Prades, R; Salas, E; Selva, J; Teixidó, M; Zurita, E, 2012) |
| "Determine whether patients with Alzheimer's disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9." | ( Bakchine, S; Bellelli, G; Black, SE; Caputo, A; Cummings, J; Downs, P; Froelich, L; Kressig, RW; Molinuevo, JL; Strohmaier, C, 2012) |
| "Progressive neurodegeneration in Alzheimer's disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD." | ( Andersen, F; Engstad, TA; Halvorsen, DS; Straume, B; Viitanen, M; Wilsgaard, T, 2012) |
| "Progressive neurodegeneration in Alzheimer's disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD." | ( Andersen, F; Engstad, TA; Halvorsen, DS; Straume, B; Viitanen, M; Wilsgaard, T, 2012) |
| "The recognition of Alzheimer's disease (AD) as a heterogeneous disorder that results from incremental pathological changes in dynamic organismic systems is essential to move beyond the unidimensional approaches to prevention and therapy that have proven largely ineffective to date." | ( Baker, LD; Cholerton, B; Craft, S, 2013) |
| "Treatment disparities in Alzheimer's disease (AD) have received little attention." | ( Armstrong, EP; Gilligan, AM; Malone, DC; Warholak, TL, 2012) |
| "Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks." | ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2012) |
| "In patients with Alzheimer's disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse." | ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2012) |
| "Salidroside may treat Alzheimer's disease by inhibiting the oxidative stress." | ( Chai, X; Kong, W; Liu, P; Shao, T; Song, L; Wen, X; Zhang, J, 2012) |
| "These adsorbents might be useful for Alzheimer's disease therapy." | ( Hiki, Y; Hori, H; Kawaguchi, K; Kitaguchi, N; Murakami, K; Nakai, S; Ohashi, A; Sugiyama, S; Suzuki, N; Takeuchi, M; Yamagawa, H; Yuzawa, Y, 2013) |
| "Currently available treatment used in Alzheimer's disease is based on acetylcholinesterase inhibitors, e." | ( Mikiciuk-Olasik, E; Szymański, P; Zurek, E, 2013) |
| "The approved treatments for Alzheimer's disease (AD) exploit mainly a symptomatic approach based on the use of cholinesterase inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists." | ( Cacciatore, I; Cerasa, LS; Cornacchia, C; Di Crescenzo, A; Di Filippo, ES; Di Stefano, A; Fontana, A; Fulle, S; Grilli, M; Laserra, S; Marchi, M; Sozio, P, 2013) |
| "Currently available therapies for Alzheimer's disease (AD) do not treat the underlying cause of AD." | ( Dey, D; Hayes, CD; Lakshmana, MK; Minond, D; Nefzi, A; Palavicini, JP; Patkar, KA; Wang, H, 2013) |
| "Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses." | ( Christensen, D; Cummings, J; Doody, R; Fain, R; Farlow, M; Liu, L; Mackell, J; Sabbagh, M, 2013) |
| "The prevalence of Alzheimer's disease (AD) is increasing rapidly worldwide due to an ageing population and largely ineffective treatments." | ( Chami, B; Sutherland, GT; Witting, PK; Youssef, P, 2013) |
| "We simulated data based on the Alzheimer's Disease Anti-Inflammatory Prevention Trial, and a range of sample sizes, biomarker positive predictive values, and treatment effects." | ( Bartlett, AL; Forrester, SN; Leoutsakos, JM; Lyketsos, CG, 2014) |
| "Methylphenidate treatment of apathy in Alzheimer's disease was associated with significant improvement in 2 of 3 efficacy outcomes and a trend toward improved global cognition with minimal adverse events, supporting the safety and efficacy of methylphenidate treatment for apathy in Alzheimer's disease." | ( Bachman, DL; Drye, LT; Herrmann, N; Lanctôt, KL; Mintzer, JE; Rosenberg, PB; Scherer, RW, 2013) |
| "Vaccine therapy for Alzheimer's disease (AD) based on the amyloid cascade hypothesis has recently attracted attention for treating AD." | ( Hirobe, S; Kamiyama, F; Kawai, Y; Matsuo, K; Nakagawa, S; Okada, N; Okamoto, H; Quan, YS, 2014) |
| "In this study, the 5X Familial Alzheimer's Disease (5XFAD) mouse model was used to investigate the effect of chronic galantamine treatment on behavior and amyloid β (Aβ) plaque deposition in the mouse brain." | ( Bhattacharya, S; Haertel, C; Maelicke, A; Montag, D, 2014) |
| "Interpreting Alzheimer's disease (AD) clinical trial (CT) outcomes is complicated by treatment dropouts and adverse events (AEs)." | ( Henley, DB; Schneider, LS; Sethuraman, G; Sundell, KL, 2015) |
| "New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal injury as equivalent." | ( Alexopoulos, P; Drzezga, A; Fellgiebel, A; Förster, S; Gray, K; Grimmer, T; Haller, B; Klupp, E; Kriett, L; Kurz, A; Laskaris, N; Perneczky, R; Yakushev, I, 2014) |
| "This system is severely affected in Alzheimer's disease (AD), and drug treatment to enhance cholinergic signaling is widely used as symptomatic therapy in AD." | ( Nathans, J; Williams, J; Wu, H, 2014) |
| "conditions mimicking an Alzheimer's Disease environment, and treated with CNS drugs in order to assess the contribution of glial cells during pharmacological treatments." | ( Francolini, M; Joshi, P; Mastrangelo, R; Matteoli, M; Ruiz, A; Verderio, C, 2014) |
| "Despite the fact that the prevalence of Alzheimer's disease (AD) is exponentially increasing, we have not yet been able to develop a new treatment to modify the course of the disease." | ( Amanatkar, HR; Grossberg, GT, 2014) |
| "Hence it is an interesting target for Alzheimer's disease (AD) therapy." | ( Biswas, D; Hameed, N; Khan, M; Rizvi, SM; Shaikh, S; Shakil, S, 2014) |
| "No disease modifying therapy exists for Alzheimer's disease (AD)." | ( Ayton, S; Bush, AI; Lei, P, 2015) |
| "Further study of Alzheimer's disease and development of treatment approaches require generalizations of knowledge on each of these components accumulated to date." | ( Mukhin, VN, 2013) |
| "Research into causes of Alzheimer's disease and its treatment has produced a tantalising array of hypotheses about the role of transition metal dyshomeostasis, many of them on the interaction of these metals with the neurotoxic amyloid-β peptide (Aβ)." | ( Barnham, KJ; Cappai, R; Curtain, CC; Kirby, N; Masters, CL; Mertens, HD; Pham, Cle L; Roberts, B; Ryan, TM, 2015) |
| "In this study, the 5X Familial Alzheimer's Disease (5XFAD) mouse model was used to investigate the effect of chronic Memogain treatment on behavior and amyloid-β (Aβ) plaque deposition in the brain." | ( Bhattacharya, S; Maelicke, A; Montag, D, 2015) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| "Current treatments for Alzheimer's disease (AD) provide modest symptomatic relief but do not slow the progression of the disease." | ( Chau, S; Chen, JJ; Herrmann, N; Lanctôt, KL; Ruthirakuhan, MT, 2015) |
| "BACE1 is an attractive target in Alzheimer's disease (AD) treatment." | ( Chennoju, K; Ghoshal, N; Manoharan, P, 2015) |
| "In the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score evaluation, a negative weighted mean difference (WMD) was observed in overall and mild-moderate groups after rivastigmine treatment." | ( Liu, Y; Ren, L; Su, J, 2015) |
| "Treatment of Alzheimer's disease (AD) with cholinesterase inhibitors (ChEI) enhances cholinergic activity and alleviates clinical symptoms." | ( Gröhn, H; Hänninen, T; Jauhiainen, AM; Miettinen, PS; Niskanen, E; Pihlajamäki, M; Soininen, H; Tarkka, IM; Vanninen, R, 2015) |
| "In the Tg2576 mouse model of Alzheimer's disease, UE2316 treatment of mice aged 14 months for 4 weeks also decreased the number of β-amyloid (Aβ) plaques in the cerebral cortex, associated with a selective increase in local insulin-degrading enzyme (involved in Aβ breakdown and known to be glucocorticoid regulated)." | ( Binnie, M; McBride, A; Noble, J; Seckl, JR; Sooy, K; Walker, BR; Webster, SP; Yau, JL, 2015) |
| "The cause of Alzheimer's disease is incompletely defined, and no truly effective therapy exists." | ( Bredesen, DE, 2015) |
| "Early diagnosis of Alzheimer's disease (AD) based on clinical criteria alone may be problematic, while current and future treatments should be administered earlier in order to be more effective." | ( Fezoulidis, I; Georgoulias, P; Hadjigeorgiou, G; Kapsalaki, E; Papatriantafyllou, J; Psimadas, D; Sifakis, N; Tsougos, I; Tzavara, C; Valotassiou, V, 2015) |
| "Apathy is a common symptom in Alzheimer's disease (AD), but no treatment has proven to be effective, although administration of cholinesterase inhibitors has been associated with moderate improvements in the short term." | ( Amenta, F; Carotenuto, A; Fasanaro, AM; Manzo, V; Rea, R; Traini, E, 2015) |
| "Hypertension, a risk factor for Alzheimer's disease (AD), is a treatable condition, which offers possibilities for prevention of AD." | ( Capone, C; Claassen, JA; Heerschap, A; Kiliaan, AJ; Mellendijk, L; Wiesmann, M; Zerbi, V, 2015) |
| "Current therapies for Alzheimer's disease (AD) can provide a moderate symptomatic reduction or delay progression at various stages of the disease, but such treatments ultimately do not arrest the advancement of AD." | ( Chai, Z; Chong, Y; Ge, C; Gu, Z; Jimenez-Cruz, CA; Liu, J; Yang, Z; Zhou, R, 2015) |
| "To successfully treat Alzheimer's disease (AD), pathophysiological events in preclinical stages need to be identified." | ( Dorostkar, MM; Herms, J; Ohli, J; Schüller, U; Shi, Y; Zou, C, 2016) |
| "Treatment of an Alzheimer's disease mouse model with genistein results in a remarkable and rapid improvement in various parameters of cognition, such as hippocampal learning, recognition memory, implicit memory, and odor discrimination." | ( Blanco-Gandía, M; Bonet-Costa, V; Borras, C; Garcia-Tarraga, P; Garcia-Verdugo, JM; Herranz-Pérez, V; Inglés, M; Mas-Bargues, C; Miñarro, J; Rodriguez-Arias, M; Viña, J, 2016) |
| "Treatment of Alzheimer's disease (AD) patients with the antidepressant fluoxetine is known to improve memory and cognitive function." | ( de Nijs, L; Hoogland, G; Prickaerts, J; Rutten, BP; Sierksma, AS; Steinbusch, HW; van den Hove, DL; van Leeuwen, FW; Vanmierlo, T, 2016) |
| "For effective immunotherapy against Alzheimer's disease, recent clinical data indicate that monoclonal antibodies directed against the amyloid-β peptide should be administered before the onset of symptoms associated with irreversible brain damage." | ( Aebischer, P; Astolfo, A; Bohrmann, B; Jacobsen, H; Kopetzki, E; Lathuilière, A; Laversenne, V; Schneider, BL; Stampanoni, M, 2016) |
| "Currently available treatments for Alzheimer's disease (AD) are disappointing and their modest benefits do not reflect the increased understanding of the condition that has arisen from the last 50 years of research or the huge investments made by the pharmaceutical industry and academia in developing therapies." | ( Howard, R; Huntley, J, 2016) |
| "Earlier diagnosis and treatment of Alzheimer's disease would greatly benefit from the identification of biomarkers at the prodromal stage." | ( Bard, F; Beglopoulos, V; Daumas, S; Fan, Z; Ferrington, L; Hyman, BT; Kelly, PA; Morris, RG; Roe, AD; Tulloch, J; Watson, R, 2016) |
| "To study the pathogenesis of Alzheimer's disease (AD) and explore the possible anti-inflammatory mechanism of tanshinone IIA (TanIIA), we evaluated the quantity of neurons and the expression levels of interleukin-1β (IL-1β), IL-6, glial fibrillary acidic protein, CD11b, C1q, C3c, and C3d in brain tissues of AD rats treated with TanIIA." | ( Li, J; Li, WW; Lu, BL; Wu, HF; Zhou, J, 2016) |
| "To date, pharmacological treatment of Alzheimer's disease (AD) includes Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for moderate-to-severe AD." | ( Galimberti, D; Scarpini, E, 2016) |
| "108 patients with senile dementia received respective treatments (54 patients per treatment, either with 100 mg/day risperidone or 2." | ( Huang, YJ; Lei, LF; Li, LH; Yuan, Y, 2016) |
| "Persons with Alzheimer's disease are at an increased risk of pneumonia, but the comparative risks during specific antidementia treatments are not known." | ( Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2017) |
| "In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks." | ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Lee, S; Levin, B; Mintzer, J; Patel, AN; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2017) |
| "Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores." | ( Ahn, J; Aisen, PS; Hebron, M; Huang, X; Moussa, C; Rissman, RA; Turner, RS, 2017) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Apathy is highly prevalent in Alzheimer's disease (AD), but whether pharmacotherapy is effective in managing apathy is unclear." | ( Hsiung, GR; Sarai, M; Sepehry, AA, 2017) |
| "Fifty individuals with Alzheimer's disease being treated at Shizuoka General Hospital were consecutively enrolled in this study from December 2009 to March 2015 (76." | ( Harada, K; Ide, K; Katsuyama, Y; Kawakami, N; Kawasaki, Y; Kim, K; Shiosaki, E; Sonoda, A; Umegaki, K; Yamada, H; Yamanaka, M; Yoshida, H, 2016) |
| "Nine month-old triple transgenic Alzheimer's disease model mice exhibited impaired short-term novel object recognition memory that was rescued by treatment with a NAAG peptidase inhibitor." | ( Balasubramanian, S; Bzdega, T; Craddock, KE; Der, EK; Hark, TJ; Janczura, KJ; Moussa, C; Neale, JH; O'Rourke, B; Olszewski, RT; Venzor, F, 2017) |
| "To date, there is no effective Alzheimer's disease (AD)-modifying therapy." | ( Koyama, N; Maeda, M; Mori, T; Segawa, T; Tan, J; Town, T, 2017) |
| "Cognitive impairment in humans with Alzheimer's disease (AD) and in animal models of Aβ-pathology can be ameliorated by treatments with the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARγ) agonists, such as rosiglitazone (RSG)." | ( Chesson, BC; Cortez, I; Denner, L; Dineley, KT; Folorunso, O; Franklin, WF; Haidacher, SJ; Hsu, WJ; Laezza, F; Lichti, CF; Nenov, MN; Rudra, JS; Sadygov, RG; Singh, AK; Taglialatela, G; Wildburger, NC, 2017) |
| "The complex pathogenic mechanisms of Alzheimer's disease (AD) include the aggregation of β-amyloid peptides (Aβ) into oligomers or fibrils as well as Aβ-mediated oxidative stress, which require comprehensive treatment." | ( Cai, S; Han, Q; Qi, C; Wang, C; Wang, X; Yang, L; Yang, R, 2017) |
| "Current options for Alzheimer's disease (AD) treatment are based on administration of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or memantine, acting as an N-methyl-D-aspartate (NMDA)." | ( Cikánková, T; Hroudová, J; Korábečný, J; Kuča, K; Mezeiová, E; Nepovimová, E; Špilovská, K; Vašková, L, 2018) |
| "The prevalence of Alzheimer's disease (AD) continues to rise, while treatment options for cognitive impairment are limited." | ( Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D, 2017) |
| "Recent studies using the mouse model of Alzheimer's disease (AD) have shown that donepezil administration reduces brain amyloid-β (Aβ) accumulation." | ( Ishibashi, K; Ishii, K; Ishiwata, K; Miura, Y; Wagatsuma, K, 2017) |
| "The clinical diagnosis and treatment of Alzheimer's disease (AD) represent a challenge to clinicians due to the variability of clinical symptomatology as well as the unavailability of reliable diagnostic tests." | ( Catt, M; Garyfallou, GZ; Ketebu, O; Mukaetova-Ladinska, EB; Şahin, S; Yu, EH, 2017) |
| "At present there is no therapy for Alzheimer's Disease which completely stops the progressive dementia effecting late onset Alzheimer's Disease (AD) patients." | ( Weinstein, JD, 2017) |
| "Due to the complexity of Alzheimer's disease, multiple cellular types need to be targeted simultaneously in order for a given therapy to demonstrate any major effectiveness." | ( D'Arrigo, JS, 2018) |
| "For effective treatment of Alzheimer's disease (AD), it is important to identify subjects who are most likely to exhibit rapid cognitive decline." | ( Choi, H; Jin, KH, 2018) |
| "Donepezil is widely used to treat Alzheimer's disease (AD), but detecting early response remains challenging for clinicians." | ( Berger, JT; Foldi, NS; Kaplan, L; Ly, JJ; Macina, LO; Stewart, JL; Van Dyk, K; Vila-Castelar, C, 2019) |
| "Therapeutics to effectively treat Alzheimer's disease (AD) are lacking." | ( Malter, JS; O'Neal, MA; Stallings, NR, 2018) |
| "Despite recent advances in Alzheimer's disease (AD) research, no breakthrough treatments have been discovered." | ( Gold, J; Grossberg, GT; Grysman, N; Khoury, R; Patel, K, 2018) |
| "Immunotherapy for Alzheimer's disease (AD) remains promising in the improvement of cognition and memory via the clearing of amyloid-β protein (Aβ) in the AD brain, despite some side effects." | ( Cao, Y; Hu, M; Qi, J; Yang, J; Zhang, J, 2018) |
| "Drug development for the treatment of Alzheimer's disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates." | ( Barykin, EP; Kozin, SA; Makarov, AA; Mitkevich, VA, 2018) |
| "In view of the multifactorial nature of Alzheimer's disease (AD), multitarget small molecules (MTSM) represent the most potent and attractive therapeutic strategy to design new drugs for Alzheimer's disease therapy." | ( Carreiras, MC; Chabchoub, F; Dgachi, Y; Iriepa, I; Ismaili, L; Janockova, J; Jun, D; Maalej, E; Malek, R; Marco-Contelles, J; Martin, H; Moraleda, I; Refouvelet, B; Sepsova, V; Soukup, O, 2019) |
| "The lack of effective treatments for Alzheimer's disease (AD) is alarming, considering the number of people currently affected by this disorder and the projected increase over the next few decades." | ( Caccamo, A; Dave, N; Ferreira, E; Huentelman, MJ; Naymik, M; Oddo, S; Piras, IS; Tran, A; Velazquez, R; Winslow, W, 2020) |
| "NSAIDs may prevent Alzheimer's disease (AD) but have failed as a treatment, possibly because only 1-2% of an oral NSAID dose reaches the brain." | ( Lehrer, S; Rheinstein, PH, 2019) |
| "Vitamin E was proposed as treatment for Alzheimer's disease many years ago." | ( Cervera-Ferri, A; Esteve, D; Lloret, A; Monllor, P, 2019) |
| "Due to complex pathogenesis of Alzheimer's disease (AD), currently there is no effective disease-modifying treatment." | ( Cao, Y; Cui, K; Pan, H; Wang, L; Wang, Y; Wu, Y; Zhang, J, 2019) |
| "Although no effective treatment for the Alzheimer's disease currently exist, some drugs acting as Acetylcholinesterase inhibitors, like galanthamine have positively affected such patients." | ( Danchev, ND; Kostadinova, I; Mihaylova, R; Tsekova, DS; Vassilev, NG; Vezenkov, LT, 2019) |
| "As a longstanding problem, Alzheimer's disease (AD) has stymied researchers in the medical field with its increasing incidence and enormous treatment difficulty." | ( Cao, H; Chen, Z; Cui, X; Guo, H; Wang, S; Yu, J; Zheng, W, 2019) |
| "Multiplexed detection of Alzheimer's disease (AD) core biomarkers is of great significance to early diagnosis and personalized treatment of AD patients." | ( Huang, J; Liu, S; Song, X; Wang, H; Wang, J; Wang, Y; Yu, J; Zhang, X, 2019) |
| "Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD." | ( Avramopoulos, D; Baksh, SN; Devanand, DP; Drye, LT; Ehrhardt, S; Ismail, Z; Lyketsos, CG; Mintzer, J; Munro, CA; Pollock, BG; Porsteinsson, AP; Rajji, TK; Rosenberg, PB; Schneider, LS; Shade, DM, 2019) |
| "The complexity of Alzheimer's disease (AD) complicates the search for effective treatments." | ( Derry, PJ; Hegde, ML; Jackson, GR; Kayed, R; Kent, TA; Tour, JM; Tsai, AL, 2020) |
| "Complex pathomechanism of Alzheimer's disease (AD) prompts researchers to develop multifunctional molecules in order to find effective therapy against AD." | ( Gobec, S; Godyń, J; Jończyk, J; Knez, D; Malawska, B; Panek, D; Pasieka, A; Sabaté, R; Valdivieso, ÁDR; Wichur, T; Więckowska, A; Więckowski, K, 2020) |
| "Symptomatic treatments of Alzheimer's Disease (AD) with cholinesterase inhibitors and/or memantine are relatively ineffective and there is a need for new treatments targeting the underlying pathology of AD." | ( Cranston, A; Harrington, CR; Klein, J; Kondak, C; Lauer, D; Magbagbeolu, M; Melis, V; Niewiadomska, G; Riedel, G; Santos, RX; Schwab, K; Steczkowska, M; Theuring, F; Wischik, CM; Wydrych, M; Zadrozny, M, 2020) |
| "The number of patients diagnosed with Alzheimer's disease (AD) increases each year, and there are currently few treatment strategies to decrease the symptoms of AD; furthermore, these strategies are not sufficient to reduce memory loss in AD patients." | ( Bello, M; Castro-Silva, ES; Correa-Basurto, J; Estrada-Pérez, A; Hernández-Rodríguez, M; Méndez-Méndez, JV; Muñoz-Ochoa, M; Murillo-Álvarez, J; Rosales-Hernández, MC; Villalobos-Acosta, D, 2021) |
| "The prevalence of Alzheimer's disease increasing day by day due to the increase in the share of the elderly population in the general population due to developing health and living conditions, is limited and early diagnosis and effective treatment possibilities are very limited." | ( Andaç Topkan, T; Bukan, N; Erel, Ö; Gündüztepe, Y; Gurbuz, N; Karaman, Y; Neşelioğlu, S; Zorlu, E, 2020) |
| "Sixty-five outpatients with Alzheimer's disease or mixed dementia being treated with donepezil were assessed at baseline and over 27 months." | ( Coin, A; De Rui, M; Devita, M; Girardi, A; Manzato, E; Pamio, MV; Pigozzo, S; Sergi, G; Trevisan, C, 2020) |
| "The lack of effective Alzheimer's disease treatment is becoming a challenge for researchers and prompts numerous attempts to search for and develop better therapeutic solutions." | ( Domanowska, A; Malinowski, B; Wiciński, M; Wódkiewicz, E, 2020) |
| "Potential drug treatments for Alzheimer's disease (AD) may be found by identifying compounds that block the assembly of the microtubule-associated protein tau into neurofibrillar tangles associated with neuron destabilization and cell death." | ( Fullwood, NJ; Hughes, E; Hussain, R; Mala, B; Middleton, DA; Siligardi, G; Townsend, DJ, 2020) |
| "Depression is highly related to Alzheimer's disease (AD), yet no effective treatment is available." | ( Chen, W; Fu, HR; Gao, YF; Wang, H; Wang, L; Wang, XD; Xu, XY; Xu, Y; Zhang, FF; Zhang, HT; Zhang, JG, 2020) |
| "Drugs for the treatment of Alzheimer's disease (AD) are in urgent demand due to the unmet need and the social burden associated with the disease." | ( Chang, HY; Su, IJ; Tsai, KJ; Wang, HC, 2020) |
| "The complications of Alzheimer's disease (AD) have made the development of its treatment a challenging task." | ( Akhtar, M; Akhter, M; Kaundal, M; Najmi, AK; Panda, BP; Parvez, S; Rahman, SO; Salman, M; Shrivastava, A, 2020) |
| "Early diagnosis of Alzheimer's disease (AD) using potential biomarkers may help with implementing early therapeutic interventions, monitoring, and ultimately disease treatment." | ( Hasanzadeh, Z; Laghousi, D; Nikanfar, M; Nourazarian, A; Sadrirad, S; Vatankhah, AM, 2021) |
| "Advanced Alzheimer's disease (AD) has no effective treatment, and identifying early diagnosis markers can provide a time window for treatment." | ( Li, D; Liang, D; Liu, Y; Nie, L; Qu, H; Wang, R; Wu, PY; Xiang, H; Xiong, Z; Yang, Z; Yao, Y; Zeng, X, 2020) |
| "The primary end point was the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog) at week 24 and the Mattis Dementia Rating Scale (MDRS) at week 76, using intention-to-treat with retrieved dropout at week 24 and observed cases at week 76, consistent with the original analyses." | ( Elango, DS; Espay, AJ; Gomez-Mancilla, B; Mahajan, A; Marsili, L; Masellis, M; Pathan, R; Pezous, N; Pilotto, A; Sturchio, A, 2021) |
| "Current drugs available in clinic for Alzheimer's disease (AD) treatment can only alleviate disease symptoms without clearly curing or delaying the process of AD." | ( Fang, L; Gou, S; Liu, Z; Xia, S; Zhang, B, 2021) |
| "The complex pathophysiology of Alzheimer's disease (AD) has prompted researchers to develop multitarget-directed molecules to find an effective therapy against the disease." | ( Akbarzadeh, T; Edraki, N; Felegari, P; Firuzi, O; Hariri, R; Iraji, A; Mahdavi, M; Mirfazli, SS; Rastegari, A; Saeedi, M, 2021) |
| "To develop drugs for treating Alzheimer's disease (AD) on the basis of the amyloid cascade hypothesis, the isolated saponins were evaluated for inhibition of BACE1 activity and amyloid beta (Aβ) aggregation using thioflavin-T assay, and triterpenes as an aglycone moiety and an alkaline hydrolysate of the saponins were also evaluated." | ( Fujihara, K; Kawazu, R; Kinoshita, K; Koyama, K; Sasaki, H; Shimoyama, T; Takahashi, K, 2021) |
| "Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
| "Compared with untreated Alzheimer's disease model mice, nanopeptide administration shortened the escape latency time in a water maze test and improved the movements in the autonomic activity test." | ( Guo, Y; Liu, R; Xu, L; Zhang, D; Zhang, J; Zhang, Z; Zhu, J, 2021) |
| "Clinical trials on Alzheimer's disease patients, however, showed several side effects that worsened the cognitive symptoms of the treated patients." | ( Chávez-Gutiérrez, L; Comaposada-Baró, R; Escribano-Saiz, JJ; Franco, ML; García-Carpio, I; Vilar, M, 2021) |
| "in the treatment of Alzheimer's disease, but there is a lack of scientific data to support the efficacy and safety of Cannabis sativa L." | ( Bala, A; Chaudhary, SK; Kumar, CS; Mahadevappa, CP; Matsabisa, MG; Mooko, T; Tripathy, S, 2022) |
| "Current strategies for the treatment of Alzheimer's disease (AD) focus on the pathology in the later stages of disease progression." | ( Jiang, Y; Li, K; Li, X; Xu, L; Yang, Z, 2021) |
| "Sporadic Alzheimer's disease (sAD) is the commonest cause of age-related neurodegeneration but there are no available treatments with demonstrated disease-modifying actions." | ( Cooper, GJS; Dowsey, AW; Philbert, SA; Unwin, RD; Xu, J, 2021) |
| "Eleven patients with Alzheimer's disease were treated with donepezil for 6 months." | ( Cheng, J; Yang, H; Zhang, J, 2021) |
| "To develop drugs to treat Alzheimer's disease (AD) on the basis of the amyloid cascade hypothesis, the amyloid-β (Aβ) aggregation inhibitory activities of 110 extracts from mushrooms were evaluated by thioflavin T (Th-T) assays." | ( Fujihara, K; Hayashi, S; Kamauchi, H; Kino, Y; Kinoshita, K; Koyama, K; Masuda, Y; Noji, M; Sasaki, H; Satoh, JI; Takanami, T, 2021) |
| "The described relationship between Alzheimer's disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD pathology." | ( Carranza-Naval, MJ; Del Marco, A; Garcia-Alloza, M; Vargas-Soria, M, 2021) |
| "The complex pathogenesis of Alzheimer's disease (AD) calls for multi-target approach for disease treatment." | ( Cao, Z; Deng, Y; Liu, X; Qiang, X; Song, Q; Yu, G; Zhang, H, 2021) |
| "Current treatments for Alzheimer's disease (AD) attenuate the progression of symptoms and aim to improve the patient's quality of life." | ( Cunha, S; Forbes, B; Silva, AC; Sousa Lobo, JM, 2021) |
| "CL2120 and CL4176 transgenic worms of Alzheimer's disease (AD) models were treated with different concentrations of nicotine, and worm paralysis was monitored." | ( Jin, Y; Li, H; Lu, X; Wang, X; Zhang, Y; Zhao, L, 2021) |
| "A total of 294 patients with Alzheimer's disease were randomly divided into a treatment group and a control group, 147 cases each group." | ( He, XY; Huang, P; Xu, M, 2021) |
| "Although Alzheimer's disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best." | ( Akinola, M; Butler, C; Chan, JYC; Davis Jones, G; Frangou, E; Galloway, J; Geddes, J; Hallam, A; Husain, M; Koychev, I; Love, S; Manohar, SG; McShane, R; Mura, S; Sen, A; Symmonds, M; Tai, XY; Thompson, S; Van Der Putt, R, 2021) |
| "The increasing numbers of elderly Alzheimer's disease (AD) patients because of a steady increase in the average lifespan and aging society attract great scientific concerns, while there were fewer effective treatments on AD progression due to unclear exact causes and pathogenesis of AD." | ( Zhang, L; Zhou, X, 2021) |
| "In the setting of Alzheimer's disease, insomnia is an even more complicated issue, with a higher overall prevalence than in the general population, greater complexity of contributing etiologies, and differences in diagnosis (at times based on caregiver observation of sleep disruption rather than subjective complaints by the individual with the disorder), and requiring more discretion in terms of treatment, particularly in regard to adverse effect profile concerns." | ( Bliwise, DL; Roland, JP, 2021) |
| "Drugs that are used in the treatment of Alzheimer's disease are donepezil, galantamine, tacrine, rivastigmine showing major adverse effects." | ( Natarajan, R; Raji, V; Sivaraman, B; Velmurugan, BA, 2022) |
| "For the potential therapy of Alzheimer's disease (AD), cholinesterases (ChE) and monoamine oxidase (MAO) are key enzymes that regulate the level of acetylcholinesterase (AChE)/butyrylcholinesterase (BChE) and monoamines." | ( Khan, JA; Nadeem, MS; Rashid, U, 2021) |
| "The pathogenesis of Alzheimer's disease (AD) is still unclear, and presently there is no cure for the disease that can be used for its treatment or to stop its progression." | ( Han, SJ; Hong, JM; Kim, IC; Kim, KH; Kim, TK; Oh, H; Yim, JH, 2021) |
| "Due to the complex nature of Alzheimer's disease (AD), it is important to investigate agents with multiple effects in the treatment of AD." | ( Celik Topkara, K; Cetinkaya, A; Demir, S; Kilinc, E; Saylan, A, 2022) |
| "Dysbiosis contributes to Alzheimer's disease (AD) pathogenesis, and oral bacteriotherapy represents a promising preventative and therapeutic opportunity to remodel gut microbiota and to delay AD onset and progression by reducing neuroinflammation and amyloid and tau proteins aggregation." | ( Bonfili, L; Cifone, MG; Eleuteri, AM; Gong, C; Lombardi, F, 2021) |
| "Tauopathies, such as Alzheimer's disease, have been the subject of several hypotheses regarding the way to treat them." | ( Bonnet, H; Boucherle, B; Boukherrouba, E; Boumendjel, A; Caburet, J; Chierici, S; Fortuné, A; Larosa, C; Lunven, L; Nguyen, KA; Peuchmaur, M, 2022) |
| "The study of Alzheimer's disease (AD), the most common cause of dementia, faces challenges in terms of understanding the cause, monitoring the pathogenesis, and developing early diagnoses and effective treatments." | ( Biase, I; Choi, SH; Ding, L; Granzier-Nakajima, T; Huang, S; Huang, SX; Ran, C; Ranasinghe, JC; Sharma, S; Tanzi, RE; Terrones, M; Wang, Z; Xue, Y; Ye, J; Zhang, C; Zhang, K, 2022) |
| "In order to treat Alzheimer's disease and other such tauopathies, one of the therapeutic strategies is to inhibit aggregation of Tau and its nucleating segments." | ( Pal, S; Paul, S; Roy, R, 2022) |
| "Donepezil is frequently used to treat Alzheimer's disease (AD) symptoms but is associated with early discontinuation." | ( Fukuda, H; Maeda, M; Murata, F; Murata, Y, 2022) |
| "MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects." | ( Delano-Wood, L; Huege, S; Iwanaga, D; Joshi, YB; Kotz, JE; Léger, GC; Light, GA; Molina, JL; Sprock, J; Swerdlow, NR; Talledo, J, 2023) |
| "MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects." | ( Delano-Wood, L; Huege, S; Iwanaga, D; Joshi, YB; Kotz, JE; Léger, GC; Light, GA; Molina, JL; Sprock, J; Swerdlow, NR; Talledo, J, 2023) |
| "MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects." | ( Delano-Wood, L; Huege, S; Iwanaga, D; Joshi, YB; Kotz, JE; Léger, GC; Light, GA; Molina, JL; Sprock, J; Swerdlow, NR; Talledo, J, 2023) |
| "Increased interest in the aging and Alzheimer's disease (AD)-related impairments in autophagy in the brain raise important questions about regulation and treatment." | ( Brewer, GJ; Harlan, BA; Martínez, RAS; Pinky, PD, 2023) |
| "There is currently no treatment for Alzheimer's disease, and the few approved medications have a low success rate in lowering symptoms." | ( Chatterjee, B; Fadnavis, M; Kuber, B, 2023) |
| "The regulation of Aβ levels in Alzheimer's disease involves cholesterol metabolism and inflammation, so this article first analyzes the biological functions of PPARγ, then mainly focuses on the relationship between cholesterol and inflammation and Aβ, and elaborates on the regulation of PPARγ on key proteins and the corresponding molecules, which provides new ideas for the treatment of AD." | ( Gu, L; Hu, M; Ju, Y; Li, Q; Zhang, X; Zheng, M, 2023) |
| "Research into the early impacts of Alzheimer's disease (AD) on synapse function is one of the most promising approaches to finding a treatment." | ( Chiantia, G; Hidisoglu, E; Marcantoni, A, 2023) |
| "Since there is no effective Alzheimer's disease (AD)-modifying therapy available currently, early analysis of AD core biomarkers has become one of great significance and common concern in clinical diagnosis." | ( Chen, Z; Feng, M; Hua, J; Luo, C; Shi, Z; Sun, J; Wang, L; Wang, M; Xu, C; Zhang, X, 2023) |
| "Experiments on transgenic mice with an Alzheimer's disease model (APP/PS1) demonstrated that the intranasal administration of liposomes within 21 days resulted in enhanced learning abilities and a reduction in the formation rate of Aβ plaques in the entorhinal cortex and hippocampus of the brain." | ( Belyaev, G; Bushmeleva, K; Gaynanova, G; Petrov, K; Samigullin, D; Sibgatullina, G; Sinyashin, O; Valeeva, F; Vasileva, L; Vyshtakalyuk, A; Zakharova, L; Zueva, I, 2023) |
| "The scores of Alzheimer's Disease Assessment Scale-Cognition in the observation group decreased after treatment (P < ." | ( Dan, Z; Li, H; Xie, J, 2023) |
| "Although Alzheimer's disease (AD) is the most common form of dementia, the effective treatment of AD is not available currently." | ( Berglund, K; Shim, SS; Yu, SP, 2023) |
| "Current treatments for Alzheimer's disease (AD) have largely failed to yield significant therapeutic benefits." | ( Hu, J; Malter, JS; O'Neal, MA; Shen, ZJ; Stallings, NR, 2023) |
| "Current treatment options for Alzheimer's disease (AD) are limited, inefficient, and often have serious side effects." | ( Koulousakis, P; Prickaerts, J; Rombaut, B; Schepers, M; van den Hove, D; Vanmierlo, T; Willems, E, 2023) |
| "Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers." | ( Bortnichak, EA; DiBello, JR; Liaw, KL; Liu, X; Lu, Y; Swartz, J; Zhong, W, 2023) |
| "Older adults with dementia including Alzheimer's disease may have difficulty communicating their treatment preferences and thus may receive intensive end-of-life (EOL) care that confers limited benefits." | ( Cohen, JT; Faul, JD; Fillit, HM; Freund, KM; Lin, PJ; Neumann, PJ; Olchanski, N; Zhu, Y, 2023) |
| "Rapid early diagnosis of Alzheimer's disease (AD) is critical for its effective and prompt treatment since the clinically available treatments can only relieve the symptoms or slow the disease progression." | ( Chen, M; Li, M; Liu, X; Su, X; Xie, Y, 2024) |
| "The number of patients with Alzheimer's disease (AD) continues to rise and, despite the efforts of researchers, there are still no effective treatments for this multifaceted disease." | ( Antunes, CM; Burke, AJ; Carreiro, EP; Costa, AR; Ernesto, S; Pinto, F; Rodrigues, B, 2023) |